

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number  
WO 01/92542 A2(51) International Patent Classification<sup>7</sup>:

C12N 15/63

(74) Agents: SILVESTON, Judith et al.; Abel &amp; Imray, 20 Red Lion Street, London WC1R 4PQ (GB).

(21) International Application Number: PCT/GB01/02394

(22) International Filing Date: 30 May 2001 (30.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0013089.8	30 May 2000 (30.05.2000)	GB
0013090.6	30 May 2000 (30.05.2000)	GB
60/287,410	1 May 2001 (01.05.2001)	US

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


(71) Applicant (for all designated States except US): ICH PRODUCTIONS LIMITED [GB/GB]; 30 Guildford Street, London WC1N 1EH (GB).

## Published:


— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INTEGRIN-TARGETING VECTORS HAVING ENHANCED TRANSFECTION ACTIVITY



WO 01/92542 A2



(57) Abstract: A complex that comprises: i) a nucleic acid; ii) an integrin-binding component; iii) a polycationic nucleic acid-binding component, for example, oligolysine; and iv) a lipid component, for example, a cationic liposome, in which complex the integrin binding component comprises an integrin-binding element and a spacer element, the spacer element being longer and/or more hydrophobic than the dipeptide spacers GG (glycine-glycine) and GA (glycine-alanine), has enhanced transfection activity.

BEST AVAILABLE COPY

**INTEGRIN-TARGETING VECTORS HAVING  
ENHANCED TRANSFECTION ACTIVITY**

The present invention relates to an improved integrin-targeting vector that has enhanced transfection activity.

The term "transfection" is used herein to denote the introduction of a nucleic acid into a cell. The nucleic acid may be of any origin and the recipient cell may be prokaryotic 10 or eukaryotic.

Gene therapy and gene vaccination are techniques that offer interesting possibilities for the treatment and/or prophylaxis of a variety of conditions, as does anti-sense therapy. Such 15 techniques require the introduction of a DNA of interest into target cells. The ability to transfer sufficient DNA to specific target cells remains one of the main limitations to the development of gene therapy, anti-sense therapy and gene vaccination. Both viral and non-viral DNA delivery systems 20 have been proposed. In some cases RNA is used instead of DNA.

Receptor-mediated gene delivery is a non-viral method of gene transfer that exploits the physiological cellular process, receptor-mediated endocytosis to internalise DNA. Receptor-25 mediated non-viral vectors have several advantages over viral vectors. In particular, they lack pathogenicity; they allow targeted gene delivery to specific cell types and they are not restricted in the size of nucleic acid molecules that can be packaged. Gene expression is achieved only if the nucleic acid 30 component of the complex is released intact from the endosome to the cytoplasm and then crosses the nuclear membrane to access the nuclear transcription machinery. However, transfection efficiency is generally poor relative to viral vectors owing to endosomal degradation of the nucleic acid 35 component, failure of the nucleic acid to enter the nucleus and the exclusion of aggregates larger than about 150nm from clathrin coated vesicles.

Integrins are a super-family of heterodimeric membrane proteins

- 2 -

consisting of several different  $\alpha$  and  $\beta$  subunits. They are important for attachment of cells to the extracellular matrix, cell-cell interactions and signal transduction. Integrin-mediated cell entry is exploited for cell attachment and entry by a number of intracellular pathogens including Trypanosoma cruzi (Fernandez et al., 1993), adenovirus (Wickham et al., 1993), echovirus (Bergelson et al., 1992) and foot-and-mouth disease virus (Logan et al., 1993) as well as the enteropathogen Y. pseudotuberculosis (Isberg, 1991). Egg-sperm fusion is also integrin mediated. Intensive study of the invasin-integrin mediated internalisation process of Yersinia pseudotuberculosis demonstrated that, for efficient cell entry, integrin-binding ligands should have a high binding affinity and a non-polar distribution (Isberg, 1991). Integrin-mediated internalisation proceeds by a phagocytic-like process allowing the internalisation of bacterial cells one to two micrometers in diameter (Isberg, 1991). Targeting of non-viral vectors to integrins, therefore, has the potential to transfect cells in a process that mimics infection of cells by pathogens and avoids the size limitation imposed by clathrin-coated vesicles in receptor-mediated endocytosis.

A further advantage of integrin-mediated vectors is that a large number of peptide ligands for integrin receptors have been described, including sequences derived from natural protein ligands [Verfaillie, 1994 #635; Wang, 1995 #645; Staatz, 1991 #539; Pierschbacher, 1984 #314; Massia, 1992 #86, Clements et al. 1994 & Lu et al, 1993] or selected from phage display libraries (Koivunen et al. 1995; 1993; 1994; O'Neil et al. 1992; Healy et al 1995; Pasqualani et al. 1995).

The conserved amino acid sequence arginine-glycine-aspartic acid (RGD) is an evolutionarily conserved feature of many, but not all, natural integrin-binding ligands such as extracellular matrix proteins and viral capsids. Peptides, particularly those containing cyclic-RGD domains can also bind integrins.

- 3 -

Peptides containing cyclic-RGD domains are particularly suitable ligands for vectors since they bind to integrins with higher affinities than linear peptides (Koivunen et al. 1995).

Hart et al. have demonstrated previously that multiple copies of a cyclic RGD peptide displayed in the major coat protein subunit of fd filamentous phage particles, approximately 900 nm in length, are internalised efficiently by cells in tissue culture in an integrin-mediated manner (Hart et al., 1994).

The phage particles were probably internalised by a phagocytic-like process as their size would exclude them from endocytosed vesicles (Hart et al., 1994).

The cyclic RGD-containing peptide GGCRGDMFGCGG [K]<sub>16</sub> [SEQ.ID.NO.:1] was synthesised with a sixteen-lysine tail for complex formation with plasmid DNA (Hart et al., 1995).

Significant levels of integrin-mediated gene expression were achieved in epithelial cell lines with the vector GGCRGDMFGCG [K]<sub>16</sub> [SEQ.ID.NO.:2] (Hart et al., 1995) and the vectors GGCRGDMFGC [K]<sub>16</sub> [SEQ.ID.NO.:3] (WO96/15811). A similar peptide [K]<sub>16</sub>GACRGDMFGCA [SEQ.ID.NO.:4], which has the sixteen-lysine domain at the N-terminus and which is easier to synthesise than the prototype peptide (WO96/15811 and Hart et al., 1997) generated better transfection levels. Integrin mediated gene expression was generally achieved at levels of about 1 to 10%. The presence of chloroquine in the transfection medium gave some enhancement of transfection in some but not all cell lines tested.

WO98/54347 relates to an invention based on the surprising observation that inclusion of a lipid component in the above oligolysine/-peptide/DNA complex increases levels of transfection of DNA from about 1 to 10% to about 50 to almost 100%. Not only is the level of transfection increased dramatically but, contrary to previous experience, the increase is observed in all cell lines tested, including endothelial, epithelial and tumour cell lines.

WO98/54347 discloses a complex that comprises

- (i) a nucleic acid, especially a nucleic acid encoding a sequence of interest,
- 5 (ii) an integrin-binding component,
- (iii) a polycationic nucleic acid-binding component, and
- (iv) a lipid component.

The complex is a transfection vector.

10 The present invention relates to modifications of the integrin-binding component of WO98/54347, which result in further improvements in transfection efficiency.

According to WO98/534347, the integrin-binding component is any 15 component that is capable of binding specifically to integrins found on the surface of cells. The integrin-binding component may be a naturally occurring integrin-binding ligand, for example, an extracellular matrix protein, a viral capsid protein, the bacterial protein invasin, a snake venom 20 disintegrin protein, or an integrin-binding fragment of any such protein. Such integrin-binding proteins and fragments thereof may be obtained from natural sources or by recombinant techniques, but they are difficult to synthesise and purify in large amounts, they require conjugation directly to DNA or RNA 25 or to polycationic elements for DNA or RNA binding, and are immunogenic in vivo.

It is preferable to use integrin-binding peptides, in particular because of their ease of synthesis, purification and storage, their potential for chemical modification, and their 30 potentially low immunogenicity in vivo. Examples of integrin-binding peptides are given in Verfaillie, 1994 #635; Wang, 1995 #645; Staatz, 1991 #539; Pierschbacher, 1984 #314; Massia, 1992 #86, Clements et al. 1994 & Lu et al, 1993; and in Koivunen et 35 al. 1995; 1993; 1994; O'Neil et al. 1992; Healy et al 1995; and Pasqualani et al. 1995.

As indicated above, peptides containing the conserved amino acid sequence arginine-glycine-aspartic acid (RGD) bind with high affinity to integrins. Accordingly, peptides comprising the RGD sequence are particularly useful. The affinity between 5 integrin and peptide ligands is influenced by the amino acid sequence flanking the RGD domain. In peptides having a cyclic region encompassing all or part of the region comprising the RGD sequence, the conformational freedom of the RGD sequence is restricted. Such peptides generally have a higher affinity for 10 integrin receptors than do their linear counterparts. Such cyclic peptides are particularly preferred. Cyclic peptides may be formed by the provision of two cysteine residues flanking the RGD sequence in the peptide, thus enabling the formation of a disulphide bond. A cysteine residue may be 15 separated from the RGD sequence by one or more residues, for example, up to six residues, or may be immediately adjacent to the RGD sequence, although preferably both cysteines are not immediately adjacent to the ends of the RGD sequence. Two further cysteine residues may be present, enabling formation of 20 two disulphide bonds.

An example of an amino acid sequence that will permit cyclisation by disulphide bond formation is CRGDMFGC [SEQ.ID.NO.:5]. A peptide that consists of or comprises the 25 sequence CRGDMFGC may advantageously be used as an integrin-binding peptide according to the present invention. Examples of peptides that comprises the sequence CRGDMFGC and that are effective integrin-binding ligands are the peptides GGCRGDMFGC [SEQ.ID.NO.:6], GGCRGDMFGCG [SEQ.ID.NO.:7], GGCRGDMFGCA 30 [SEQ.ID.NO.:8] and GACRGDMFGCA [SEQ.ID.NO.:9].

The peptide GACDCRGDCFCA [SEQ.ID.NO.:10] has the potential to form two disulphide bonds for stabilising the RGD loop. That peptide and others having the potential to form two RGD- 35 stabilising disulphide bonds by the presence of two or more cysteine residues, may be particularly useful as integrin-

binding ligands according to the present invention.

However, not all integrin-binding peptides contain the conserved RGD sequence. For example, the peptides GACRRETAWACA [SEQ.ID.NO.:11] and GACRRETAWACG [SEQ.ID.NO.:12] are integrin-specific peptides. Other peptides comprising the sequence CRRETAWAC [SEQ.ID.NO.:13] may be used, as may other non-RGD peptides, particularly those that have the potential for disulphide bond formation by the provision of two or more 10 cysteine residues.

Peptide sequences may be designed on the basis of known ligands, for example, on the basis of integrin-binding domains of naturally-occurring integrin-binding ligands, or on the 15 basis of known peptides that bind to integrins.

As stated above integrins are a family of heterodimeric proteins found on the surface of cells. They consist of several different  $\alpha$  and  $\beta$  subunits. Some integrins are found on many 20 types of cells, others are more specific, for example,  $\alpha 5$  and  $\alpha v$  integrins are widespread and are found on a diverse range of cells. Integrin-binding ligands can vary in their affinity for different integrins. For example, GACRGDMFGCA [SEQ.ID.NO.:9] (peptide 1) has affinity for  $\alpha 5$  and  $\alpha v$  integrins but is non-specific (O'Neil et al. 1992, Hart et al. 1997). GACDCRGDCFCA [SEQ.ID.NO.:10] (peptide 5) has high affinity for integrin  $\alpha v$  but is not  $\alpha v$ -specific (Koivunen et al. 1995; Hart et al. 1997). GACRRETAWACG [SEQ.ID.NO.:12] (peptide 6) however, which does not contain the conserved RGD region, is  $\alpha 5\beta 1$ -specific 30 (Koivunen et al. 1995). Various integrin-binding peptides and their integrin specificity are set out in the Table below:

TABLE

<u>Peptide number and integrin specificity</u>	<u>Sequence</u>	<u>SEQ.ID.NO.</u>
--	-----------------	-------------------

Peptide 1 ( $\alpha$ v, $\alpha$ 5 $\beta$ 1)	GACRGDMFGCA	SEQ.ID.NO.: 9
Peptide 2 ( $\alpha$ v, $\alpha$ 5 $\beta$ 1)	GACRGDMFGCGG	SEQ.ID.NO.: 14
Peptide 5 ( $\alpha$ v)	GACDCRGDCFCA	SEQ.ID.NO.: 10
5 Peptide 6 ( $\alpha$ 5 $\beta$ 1)	GACRRETAWACG	SEQ.ID.NO.: 12
Peptide 7 ( $\alpha$ 4 $\beta$ 1)	GAGPEILDVPST	SEQ.ID.NO.: 15
Peptide 8 ( $\alpha$ 4 $\beta$ 1)	GACQIDSPCA	SEQ.ID.NO.: 16
Peptide 9 ( $\alpha$ 5 $\beta$ 1)	GACRRETAWACGKGACRRETAWACG	
		SEQ.ID.NO.: 17

10

In the various peptides described above by sequence, the initial residues "GG" or "GC", where present, are spacers. The present invention is based on the observation that modifying the spacer can improve transfection efficiency.

15

Accordingly, the present invention provides a complex that comprises

(i) a nucleic acid, especially a nucleic acid encoding a sequence of interest,

20 (ii) an integrin-binding component,

(iii) a polycationic nucleic acid-binding component, and

(iv) a lipid component,

in which complex the integrin binding component comprises an integrin-binding element and a spacer element, the spacer 25 element being longer and/or more hydrophobic than the dipeptide spacers GG (glycine-glycine) and GA (glycine-alanine).

A spacer element of the present invention is generally a peptide, that is to say, it comprises amino acid residues. The 30 amino acids may be naturally occurring or non-naturally occurring. They may have L- or D-configuration.

A spacer of the present invention may be longer than a dipeptide. It may, for example, comprise three or more amino 35 acids, for example, four or more, for example, five or more, for example, up to ten amino acids or more. The amino acids may

be the same or different, but the use of multiple lysine residues should be avoided in the spacer as oligolysine sequences are the preferred polycationic nucleic acid-binding component of a complex of the present invention.

5

The spacer may be more hydrophobic than the dipeptides GG and GA. For example, amino acids that are more hydrophobic than glycine and alanine may be used. Examples of hydrophobic amino acids are well known and include  $\epsilon$ -amino hexanoic acid.

10

A spacer may be either longer or more hydrophobic than the dipeptides GG and GA, or it may be both longer and more hydrophobic.

15 An example of the latter type of spacer is

X SXGA [SEQ.ID.NO.:18], wherein

S = serine, G = glycine, A = alanine and X =  $\epsilon$ -amino hexanoic acid. This spacer is highly hydrophobic.

20 The spacer is generally at the N-terminus of the integrin-binding peptide.

The non-spacer element of the integrin-binding component may be any of the integrin-binding peptides or polypeptides described 25 above. For example, it may be a naturally occurring integrin-binding ligand, for example, an extracellular matrix protein, a viral capsid protein, the bacterial protein invasin, a snake venom disintegrin protein, or an integrin-binding fragment of any such protein. Such integrin-binding proteins and fragments 30 thereof may be obtained from natural sources or by recombinant techniques. As indicated above, it is generally preferable to use an integrin-binding peptide, examples of which are given above. It will be appreciated that in many cases the integrin binding peptides described above comprise both an integrin- 35 binding peptide element and a spacer dipeptide GG or GC, see for example, the peptides of SEQ.ID.NO: 6, which comprises the

- 9 -

integrin-binding element CRGDMFGC and the dipeptide spacer GG. The spacer element of the present invention takes the place of a GG or GA spacer in peptides described above that comprises such a GG or GA spacer.

5

For example, integrin binding peptides include the following:

CRGDMFGC [SEQ.ID.NO.:5]; CRGDMFGCG [SEQ.ID.NO.:19];  
CRGDMFGCA [SEQ.ID.NO.:20]; CDCRGDCFCA [SEQ.ID.NO.:21];  
CRRETAWACA [SEQ.ID.NO.:22]; CRRETAWACG [SEQ.ID.NO.:23];  
10 CRGDMFGCGG [SEQ.ID.NO.:24]; GPEILDVPST [SEQ.ID.NO.:25];  
CQIDSPCA [SEQ.ID.NO.:26]; CRRETAWACGKGACRRETAWACG  
[SEQ.ID.NO.:27]. Further suitable peptides are described, for example, in WO95/14714.

15 A spacer of the present invention may be linked to any of the above peptide, preferably at the N-terminus thereof.

In a complex of the present invention, the nucleic acid, the polycationic nucleic acid-binding component and the lipid 20 component are preferably as described in WO98/54347, and as set out below.

The nucleic acid may be obtained from natural sources, or may be produced recombinantly or by chemical synthesis. It may be 25 modified, for example, to comprise a molecule having a specific function, for example, a nuclear targeting molecule. The nucleic acid may be DNA or RNA. DNA may be single stranded or double stranded. The nucleic acid may be suitable for use in gene therapy, in gene vaccination or in an anti-sense therapy. 30 The nucleic acid may be or may relate to a gene that is the target for particular gene therapy that is to say, a gene for newer treatment by gene therapy is desired; for example, a gene having a mutation, or another defect, or a gene that is deficient, or a gene that is deficient, or a gene that is 35 absent or is present in insufficient amounts or that is present in excess, any of which effects causes a disease or disorder.

- 10 -

The nucleic acid may be a molecule that can function as a gene vaccine or as an anti-sense therapeutic agent. The nucleic acid may be or correspond to a complete coding sequence or may be part of a coding sequence or may be a control or regulatory element or may be or correspond to a genetic sequence comprising all or some elements selected from the coding sequence of a gene and the upstream and downstream non translated sequences, including control and regulatory elements.

10

Alternatively, the nucleic acid may encode a protein that is commercially useful, for example industrially or scientifically useful, for example an enzyme; pharmaceutically useful, for example, a protein that can be used therapeutically or prophylactically as a medicament or vaccine; or diagnostically useful, for example, an antigen for use in an ELISA. Host cells capable of producing commercially useful proteins are sometimes called "cell factories".

20 Appropriate transcriptional and translational control elements are generally provided when the nucleic acid is a protein coding sequence. For gene therapy, the nucleic acid component is generally presented in the form of a nucleic acid insert in a plasmid or vector. In some cases, however, it is not necessary to incorporate the nucleic acid component in a vector in order to achieve expression. For example, gene vaccination and anti-sense therapy can be achieved using a naked nucleic acid.

30 The nucleic acid is generally DNA but RNA may be used in some cases, for example, in cancer vaccination. The nucleic acid component may be referred to below as the plasmid component or component "D".

35 The polycationic nucleic acid-binding component is any polycation that is capable of binding to DNA or RNA is

- 11 -

retained. For example, from 4 to 100 cationic monomers may be present, for example, from 10 to 20, especially about 16. An oligolysine is particularly preferred, for example, having from 3 to 100 lysine residues, for example, from 10 to 20, for example, from 13 to 19, for example, from 14 to 18, for example, from 15 to 17 residues, especially 16, 17 or 18 residues especially  $[K]_{16}$ , "K" denoting lysine.

The polycationic DNA or RNA-binding component may advantageously be linked or otherwise attached to the integrin-binding component. A combined integrin-binding component/polycationic DNA or RNA-binding component may be referred to below as component "I". For example, a polycationic DNA or RNA-binding component may be chemically bonded to an integrin-binding component, for example, by a peptide bond in the case of an oligolysine. The polycationic component may be linked at any position of the integrin-binding component. Preferred combinations of integrin-binding component and polycationic DNA or RNA-binding component are an oligolysine, especially  $[K]_{16}$ , linked via a peptide bond to a peptide, for example, a peptide as described above.

A combined integrin-binding component/polycationic DNA or RNA-binding component is a component having an integrin-binding moiety that is the integrin-binding component as defined and described herein linked or otherwise attached to a polycationic DNA or RNA binding moiety that is a polycationic DNA or RNA component as defined and described herein.

The polycationic DNA or RNA-binding component may advantageously be linked or otherwise attached to the integrin-binding component. A combined integrin-binding component/polycationic DNA or RNA-binding component may be referred to below as component "I". For example, a polycationic DNA or RNA-binding component may be chemically bonded to an integrin-binding component, for example, by a peptide bond in the case of an

- 12 -

oligolysine. The polycationic component may be linked at any position of the integrin-binding component. Preferred combinations of integrin-binding component and polycationic DNA or RNA-binding component are an oligolysine, especially  $[K]_{16}$ , 5 linked via a peptide bond to a peptide, for example, a peptide as described above.

It is disclosed in WO98/54347 that the use of a lipid greatly enhances transfection for all peptides and all cell types 10 tested, unlike other enhancement techniques that have been tried, for example, chloroquine, which enhance transfection to a small extent in some but not all cell types tested.

The lipid component may be or may form a cationic liposome. 15 The lipid component may be or may comprise one or more lipids selected from cationic lipids and lipids having membrane destabilising or fusogenic properties, especially a combination of a cationic lipid and a lipid that has membrane destabilising properties.

20

A preferred lipid component ("L") is or comprises the neutral lipid dioleyl phosphatidylethanolamine, referred to herein as "DOPE". DOPE has membrane destabilising properties sometimes referred to as "fusogenic" properties (Farhood et al. 1995). 25 Other lipids, for example, neutral lipids, having membrane destabilising properties, especially membrane destabilising properties like those of DOPE may be used instead of or as well as DOPE.

30 Other phospholipids having at least one long chain alkyl group, for example, di(long alkyl chain)phospholipids may be used. The phospholipid may comprise a phosphatidyl group, for example, a phosphatidylalkanolamine group, for example, a phosphatidyl-ethanolamine group.

35

A further preferred lipid component is or comprises the

- 13 -

cationic lipid N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride, referred to herein as "DOTMA". DOTMA has cationic properties. Other cationic lipids may be used in addition to or as an alternative to DOTMA, in particular cationic lipids having similar properties to those of DOTMA. Such lipids are, for example, quaternary ammonium salts substituted by three short chain alkyl groups, and one long chain alkyl group. The short chain alkyl groups may be the same or different, and may be selected from methyl and ethyl groups. At least one and up to three of the short chain alkyl group may be a methyl group. The long alkyl chain group may have a straight or branched chain, for example, a di(long chain alkyl)alkyl group.

15 Another preferred lipid component is or comprises the lipid 2,3-dioleyloxy-N-[2-(spermidinecarboxamido)ethyl]-N,N-dimethyl-1-propanaminiumtrifluoridoacetate, referred to herein as "DOSPA". Analogous lipids may be used in addition to or as an alternative to DOSPA, in particular lipids having similar properties to those of DOSPA. Such lipids have, for example, different short chain alkyl groups from those in DOSPA.

A preferred lipid component comprises DOPE and one or more other lipid components, for example, as described above.

25 Especially preferred is a lipid component that comprises a mixture of DOPE and DOTMA. Such mixtures form cationic liposomes. An equimolar mixture of DOPE and DOTMA is found to be particularly effective. Such a mixture is known generically as "lipofectin" and is available commercially under the name 30 "Lipofectin". The term "lipofectin" is used herein generically to denote an equimolar mixture of DOPE and DOTMA. Other mixtures of lipids that are cationic liposomes having similar properties to lipofectin may be used. Lipofectin is particularly useful as it is effective in all cell types tested.

35

A further preferred lipid component comprises a mixture of DOPE

- 14 -

and DOSPA. Such mixtures also form cationic liposomes. A mixture of DOPE and DOSPA in a ratio by weight 3:1 DOSPA:DOPE is particularly effective. Such a mixture, in membrane filtered water, is available commercially under the name "Lipofectamine". Mixtures comprising DOPE, DOTMA and DOSPA may be used, for example, mixtures of lipofectin and lipofectamine.

Other cationic lipids are available commercially, for example, DOTAP (Boehringer-Mannheim) and lipids in the Tfx range 10 (Promega). DOTAP is N-[1-(2,3-diolyloxy)propyl]-N,N,N-trimethylammonium methylsulphate. The Tfx reagents are mixtures of a synthetic cationic lipid [N,N,N',N'-tetramethyl-N,N'-bis(2-hydroxyethyl)-2,3-di(oleoyloxy)-1,4-butanediammonium iodide and DOPE. All the reagents contain the same amount of 15 the cationic lipid component but contain different molar amounts of the fusogenic lipid, DOPE.

However, lipofectin and lipofectamine appear to be markedly more effective as the lipid component in LID complexes of the 20 present invention than are DOTPA and Tfx agents.

The effectiveness of a putative integrin-binding component, polycationic DNA or RNA-binding component, or of lipid component may be determined readily using the methods described 25 herein.

The efficiency of transfection using a complex of the invention is influenced by the ratio lipid component:integrin-binding component:DNA or RNA. For any chosen combination of components 30 for any particular type of cell to be transfected, the optimal ratios can be determined simply by admixing the components in different ratios and measuring the transfection rate for that cell type, for example, as described herein.

35 For example, a combination consisting of a pGL2 plasmid, which is a plasmid encoding luciferase (a reporter gene) under an

- 15 -

SV40 promoter as DNA component (D),  $[K]_{16}$ GACRGDMFGCA [SEQ.ID.NO.:9] ( $[K]_{16}$ -peptide 1) as a combined integrin-binding component/polycationic DNA binding component (I), and lipofectin (DOPE:DOTMA 1:1 molar ratio) as the lipid component (L) was tested to find the optimal ratio of components. Complexes formed with 1  $\mu$ g of lipofectin (L) and 4  $\mu$ g of  $[K]_{16}$ -peptide (I) per 1  $\mu$ g of plasmid (D) were 100-fold more active than complexes lacking lipofectin. Addition of larger amounts of lipofectin reduced transfection activity in a lipofectin dose-  
dependent manner.

An optimal transfection ratio of 0.75  $\mu$ g of lipofectin (L) per 4  $\mu$ g of the  $[K]_{16}$ -peptide integrin-binding component/-polycationic DNA or RNA-binding component (I) per 1  $\mu$ g plasmid DNA or RNA (nucleic acid component, D) was found for three different cell lines namely melanoma cell, endothelial cells and epithelial cells. That ratio was subsequently found to be effective for other different cell lines and for other oligo-lysine-peptides. A ratio L:I:D of 0.75:4:1 by weight corresponds to a molar ratio of 0.5 nmol lipofectin: 1.25 nmol  $[K]_{16}$ -peptide 6: 0.25 pmol plasmid pGL2-control. A ratio L:I:D of 0.75:4:1 by weight, or the corresponding molar ratio are preferred when lipofectin is used as the lipid component.

For a combination of components in which lipofectin is replaced by lipofectamine (DOPE/DOSPA), the optimal ratio was found to be 12  $\mu$ g lipofectamine: 4  $\mu$ g  $[K]_{16}$ -peptide 6: 1  $\mu$ g plasmid DNA or RNA. A ratio of L:I:D of 12:4:1 by weight, or the corresponding molar ratio, is appropriate for lipofectamine-containing complexes. Optimal ratios for other systems may be determined analogously.

Lipofectin and lipofectamine appear to be particularly effective in enhancing transfection. Lipofectin has the advantage that only very small amounts are required. Any side effects that may occur are therefore minimised. As indicated above,

- 16 -

the optimal weight ratio of components L:I:D when using lipofectamine is 12:4:1. With lipofectin the optimal ratio is only 0.75:4:1.

5 The present invention provides a process for the production of a transfection complex of the present invention, which comprises admixing components (i), (ii), (iii) and (iv).

Although the components may be admixed in any order, it is 10 generally preferable that the lipid component is not added last. In the case where there is a combined integrin-binding component/polycationic DNA or RNA-binding component it is generally preferable to combine the components in the following order: lipid component; combined integrin-binding/polycationic 15 DNA or RNA-binding component; DNA or RNA component, for example, in the order: lipofectin, oligolysine-peptide component, DNA or RNA component.

The present invention also provides a mixture comprising an 20 integrin-binding component, a polycationic nucleic acid-binding component, and a lipid component.

Such a mixture may be used to produce a nucleic acid-containing 25 transfection complex of the invention by the incorporation of a nucleic acid with the mixture, for example, by admixture.

Alternatively, the mixture of the invention may be used for the production of a complex which comprises, instead of the nucleic acid component, any other component that is capable of binding to the polycationic nucleic-acid binding component, for 30 example, a protein.

The present invention further provides a process for the production of a complex of the present invention, which comprises admixing a nucleic acid with a mixture of the invention.

35

The individual components of a mixture of the invention are

each as described above in relation to the complex of the invention. The preferred components, preferred combinations of components, preferred ratios of components and preferred order of mixing, both with regard to the mixture and to the production of a complex, are as described above in relation to the complex of the invention.

A mixture of the present invention preferably comprises an equimolar mixture of DOPE and DOTMA (lipofectin) as the lipid component and an oligolysine-peptide especially a  $[K]_{16}$ -peptide as a combined integrin-binding/nucleic acid-binding component.

The preferred molar ratio lipofectin:oligolysine-peptide is 0.75:4.

15 The present invention provides a method of transfecting a cell with a nucleic acid, which comprises contacting the cell in vitro or in vivo with a complex of the present invention under conditions suitable for effecting transfection, for example, as described in the Examples herein.

20 The present invention also provides a process for expressing a nucleic acid in a host cell, which comprises bringing the cell into contact with a complex of the present invention. The host cell is then cultured under conditions that enable the cell to 25 express the nucleic acid.

The present invention further provides a process for the production of a protein, which comprises contacting a host cell in vitro or in vivo with a complex of the present invention under 30 conditions suitable for effecting transfection, culturing the host cell under conditions suitable for protein expression, allowing the cell to express the protein, and obtaining the protein. The host cell may be transfected in vitro with a nucleic acid by means of a complex of the present invention and 35 cultured, the protein being obtained either from the host cell or from the culture medium.

The present invention further provides a cell transfected with a complex of the present invention, and also the progeny of such a cell.

5

The present invention also provides a pharmaceutical composition which comprises a complex of the present invention in admixture or conjunction with a pharmaceutically suitable carrier. The composition may be a vaccine.

10

The present invention also provides a method for the treatment or prophylaxis of a condition caused in a human or in a non-human animal by a defect and/or a deficiency in a gene, which comprises administering a complex of the present invention to 15 the human or to the non-human animal in an amount effective for said treatment or prophylaxis.

The present invention also provides a method for therapeutic or prophylactic immunisation of a human or of a non-human animal, 20 which comprises administering a complex of the present invention to the human or to the non-human animal in an amount effective for said therapeutic or prophylactic immunisation.

The present invention also provides a method of anti-sense 25 therapy of a human or of a non-human animal, wherein a complex of the present invention comprising anti-sense DNA is administered to the human or to the non-human animal in an amount effective for said anti-sense therapy.

30 The present invention further provides a complex of the present invention for use as a medicament and/or vaccine, for example for the prophylaxis of a condition caused in a human or in a non-human animal by a defect and/or a deficiency in a gene, for therapeutic or prophylactic immunisation of a human or of a 35 non-human animal, or for anti-sense therapy of a human or of a non-human animal.

The present invention also provides the use of a complex of the present invention for the manufacture of a medicament for the prophylaxis of a condition caused in a human or in a non-human animal by a defect and/or a deficiency in a gene, for therapeutic or prophylactic immunisation of a human or of a non-human animal, or for anti-sense therapy of a human or of a non-human animal.

10 A non-human animal is, for example, a mammal, bird or fish, and is particularly a commercially reared animal.

The DNA or RNA in the complex of the invention is appropriate for the intended gene therapy, gene vaccination, or anti-sense 15 therapy. The DNA or RNA and hence the complex is administered in an amount effective for the intended purpose.

In a further embodiment, the present invention provides a kit suitable for preparing a mixture of the present invention.

20 Such a kit comprises the following: (i) an integrin-binding component as defined above; (ii) a polycationic nucleic acid-binding component, (iii) a lipid component and, optionally, (iv) an agent that disrupts cell-cell junctions.

25 A kit suitable for producing a complex of the present invention may comprise components (i) to (iv) above and (v) either a nucleic acid or a plasmid or vector suitable for the expression of a nucleic acid, the plasmid or vector being either empty or comprising the nucleic acid.

30

The components of a kit are, for example, as described above in relation to a complex or a mixture of the present invention. Preferred components are as described above.

35 A kit generally comprises instructions for the production of a complex or a mixture of the present invention. The instruc-

- 20 -

tions preferably indicate the preferred ratios of the components and the preferred order of admixing the components, for example, as described above. A kit may be used for producing a complex suitable for gene therapy, gene vaccination or anti-sense therapy. Alternatively, it may be used for producing a complex suitable for transfecting a host cell with a nucleic acid encoding a commercially useful protein i.e. to produce a so-called "cell factory".

10 The kit of the present invention enables the user to produce quickly and easily a highly efficient transfection complex of the present invention using any DNA or RNA of choice.

A kit of the invention may comprises the following components:  
15 (a) an integrin-binding component as defined above, (b) a polycationic nucleic acid-binding component, (c) a lipid component, (d) a nucleic acid and optionally (e) an agent that disrupts cell-cell junctions.

20 Such a kit is suitable for the production of a complex for use, for example, in gene vaccination or anti-sense therapy.

In a kit of the invention the components including the preferred components are, for example, as described above in 25 relation to a complex of the present invention.

The present invention also provides a lipid component as described above for use in increasing the efficiency of transfection of a cell with a nucleic acid, either DNA or RNA, 30 the lipid component being used in combination with an integrin-binding component as defined above and a polycationic nucleic acid-binding component.

The present invention also provides the use of a lipid component as described above for the manufacture of a 35 medicament comprising

- 21 -

- (i) a nucleic acid, especially a nucleic acid encoding a sequence of interest,
- (ii) an integrin-binding component as defined above,
- (iii) a polycationic nucleic acid-binding component and
- 5 (iv) the lipid component.

The medicament may be for gene therapy, gene vaccination, or anti-sense therapy.

10 The present invention also provides a complex that comprises

- (i) a nucleic acid, especially a nucleic acid encoding a sequence of interest,
- (ii) an integrin-binding component as defined above, and
- (iii) a polycationic a nucleic acid-binding component,

15 characterised in that a lipid component, for example as described above, is an additional component of the complex.

The present invention also provides a method for increasing the efficiency of a complex that comprises

20 (i) a nucleic acid, especially a nucleic acid encoding a sequence of interest,

(ii) an integrin-binding component as defined above, and

(iii) a polycationic a nucleic acid-binding component,

characterised in that a lipid component, for example as

25 described above, is incorporated as an additional component of the complex.

In each case, the various components are as described above. The lipid component is, for example, a mixture of DOPE and

30 DOSPA or, especially, a mixture of DOPE and DOTMA, in particular an equimolar mixture of DOPE and DOTMA (lipofectin).

Targets for gene therapy are well known and include monogenic disorders, for example, cystic fibrosis, various cancers, and

35 infections, for example, viral infections, for example, with HIV. For example, transfection with the p53 gene offers great

- 22 -

potential for cancer treatment. Targets for gene vaccination are also well known, and include vaccination against pathogens for which vaccines derived from natural sources are too dangerous for human use and recombinant vaccines are not always effective, for example, hepatitis B virus, HIV, HCV and herpes simplex virus. Targets for anti-sense therapy are also known.

Further targets for gene therapy and anti-sense therapy are being proposed as knowledge of the genetic basis of disease increases, as are further targets for gene vaccination.

10

Complexes of the present invention have been demonstrated to transfect various different cell types, including endothelial and epithelial cells, and tumour cells. Transfection of all cell types tested including cell types that are particularly 15 resistant to transfection with most plasmid transfection vectors, for example, neuroblastoma cells, primary smooth muscle cells and cardiac myocytes, and haematopoieic cells has been achieved with high efficiency using transfection complexes of the present invention. This enables effective gene therapy, 20 gene vaccination and anti-sense therapy without the previous restrictions as to cell type. For example, transfection with the p53 gene for cancer therapy has great potential but is currently limited by the range of cell types in which effective transfection can be achieved.

25

The effective transfection of neuroblastoma cells demonstrates that the complexes of the invention may be used as vaccines or for therapy of neuroblastoma, an important childhood malignancy. The effective transfection of primary smooth muscle 30 cells and cardiac myocytes, which are particularly resistant to plasmid-mediated transfection, demonstrates that diseases and other pathological conditions affecting muscles and the cardiovascular system can now be treated by gene therapy. One such condition is restenosis. After balloon angioplasty 35 plaques reform in 30-50% of cases. A gene that prevents proliferation of cells in blood vessel walls may be introduced

using a complex of the present invention to reduce restenosis.

Haematopoietic cells are another cell type that is particularly resistant to plasmid-mediated transfection. The effectiveness of transfection using a complex of the present invention, which can exceed 60%, now enables gene therapy, gene vaccination and anti-sense therapy of diseases involving haematopoietic cells, including leukaemia and bone marrow stem cell disorders. For example, transfection of a cytokine gene may be used for adjuvant immunotherapy.

Complexes of the invention have been demonstrated to be effective vectors for intracellular transport and delivery of anti-sense oligonucleotides, which enables antiviral and cancer therapy.

Furthermore, complexes of the invention have been demonstrated to be effective for intracellular transport of very large DNA molecules, for example, DNA larger than 125kb, which is particularly difficult using conventional vectors. This enables the introduction of artificial chromosomes into cells.

Transfection at high levels has been demonstrated *in vivo*, confirming the utility of the complexes of the invention for gene therapy, antisense therapy and gene vaccination.

Transfection of the airways, for example, the bronchial epithelium demonstrates utility for gene therapy of, for example, cystic fibrosis and asthma. Transfection of corneal endothelium demonstrates utility for treatment of eye disease affecting the cornea or corneal organ transplants, for example in glaucoma.

The high levels of transfection make the complex of the invention particularly suitable for the production of host cells capable of producing a desired protein, so-called "cell factories". For long-term production, it is desirable that the

- 24 -

introduced nucleic acid is incorporated in the genome of the host cell, or otherwise stably maintained. That can be readily ascertained. As indicated above, the range of proteins produced in this way is large, including enzymes for scientific and industrial use, proteins for use in therapy and prophylaxis, immunogens for use in vaccines and antigens for use in diagnosis.

The present invention provides a non-viral vector that is capable of high efficiency transfection. In a preferred embodiment, the vector comprises four modular elements; an oligolysine, especially  $[K]_{16}$ , DNA or RNA-binding element; a high affinity integrin-binding peptide, for example, a peptide described herein; a DNA or RNA sequence, optionally in a plasmid, and optionally regulated by a viral promoter and an enhancing element; the cationic liposome DOTMA/DOPE (lipofectin). The combination of oligolysine-peptide/DNA or RNA complex with the cationic liposome formulation DOTMA/DOPE is a potent combination. Alternatively a DOPE/DOSPA formulation may be used instead of or in addition to a DOTMA/DOPE formulation.

The optimisation of variables associated with complex formation and the mode of transfection by LID complexes has been demonstrated. In addition, analysis by atomic forces microscopy has been carried out to assess the structure of the complexes.

The most important variables in the formation of optimal LID transfection complexes appear to be the ratio of the three components and their order of mixing. The same composition appears to be optimal for all cell lines tested.

The mechanism of action of the complex of the present invention, the reason for the unexpectedly high levels of transfection and the surprisingly wide variety of cells that can be transfected at that high efficiency are not yet understood.

- 25 -

However, the following observations made as a result of the present invention indicate that the role of the lipid component is to enhance the efficiency of transfection mediated by oligo-  
5 lysine-peptide/DNA or RNA complexes:

The level of transfection with LID (lipofectin/[K]<sub>16</sub>-peptide/plasmid) complexes is three to six fold higher than that with LKD (lipofectin/[K]<sub>16</sub>/plasmid) complexes prepared with 10 the same charge ratios, or with LD (lipofectin/plasmid) complexes. This indicates that the integrin-targeting moiety, i.e. the peptide, is a significant factor in the transfection efficiency of those complexes.

15 Optimised LID transfection complexes contain only one seventh of the amount of lipofectin required for optimal transfection with LD complexes. Transfections with low-ratio LD complexes that contain the same ratio of lipofectin to [K]<sub>16</sub>-peptide/-plasmid as in optimal LID complexes but no [K]<sub>16</sub>-peptide, did 20 not transfect cells at all. This suggests that the role of lipofectin in LID complexes is to enhance transfection mediated by the integrin receptor-binding peptide.

Furthermore, we have found that both LID and ID complexes both 25 form spherical particles of similar sizes. Optimal LD complexes, however, formed a tubular network with some tubule-associated particles, which suggests a different type of cellular interaction and transfection mechanism from LID and ID transfections.

30

It is possible that condensation of plasmid DNA or RNA by the oligolysine element of the integrin-targeting oligolysine-peptides and the cationic charge of the complexes may lead to high levels of expression when associated with lipofectin, and 35 the integrin targeting moiety i.e. the peptide is irrelevant. Transfection experiments with LKD complexes, mixed in the same

order and the same charge ratios as the LID complexes, were more efficient than LD or KD complexes. To assess the contribution of the relative importance of the oligolysine element and the integrin-targeting peptide domain of the combined 5 integrin-binding component/polycationic DNA or RNA-binding component I, transfection by LID complexes were prepared containing a range of proportions of  $[K]_{16}$  and  $[K]_{16}$  integrin targeting peptide 6,  $[K]_{16}$ GACRRETAWACG [SEQ.ID.NO.:35]. Transfection expression data indicate higher efficiencies with complexes in 10 which increasing amounts of  $[K]_{16}$  peptide 6 replace  $[K]_{16}$  and a dose-dependency on the amount of integrin-targetting (ligand-binding) domain i.e. peptide 6.

The ratio of components mixed together to form the optimal 15 transfection complex is also informative as to the possible mechanism of lipofectin mediated enhancement. The DOTMA element of lipofectin is cationic, which may enhance the activity of the complex, while DOPE may have the ability to destabilise the endosomal membrane (Farhood et al., 1995) 20 enhancing endosomal release of plasmid DNA or RNA. The components of the LID complexes are mixed together in constant optimal ratios. It is assumed that the particles formed also contain these elements in the same proportions. Therefore, 3 nmol negative charge from plasmid DNA or RNA are associated 25 with approximately 21 nmol positive charge from the  $[K]_{16}$ -peptide. Lipofectin, however, provides only a further 0.25 nmol of positive charge. This suggests that, contrary to expectations, the enhancing effect of lipofectin in LID complexes is not charge related but may relate to the membrane 30 destabilising effect of the DOPE component.

While not limited to the following theory of the mechanism of action, the following model of the early stages of the transfection process, which is based on the observations 35 described herein, is proposed to explain the surprising and unexpected high efficiency of transfection by LID complexes,

- 27 -

which high efficiency is found in all the cell types investigated.

The complexes are formed electrostatically by random 5 association of lipofectin, oligolysine-peptide and plasmid DNA or RNA. The relative high proportion of oligolysine-peptide ensures a high proportion of integrin-targeting ligands per plasmid molecule. Particles are formed that contain one or more plasmids, associated with thousands of oligolysine-peptides and, therefore, a very high concentration of integrin-targeting ligands. By mixing lipofectin with the oligolysine-peptide, then adding plasmid DNA or RNA complexes are formed containing all three components. The particles, due to the high density of ligands, have a high avidity for integrins on 15 cell surfaces, bind and are internalised by a phagocytic process (Hart et al., 1994). The vesicles fuse to form endosomes where, under acid conditions, the DOPE element contained within the particles mediates destabilisation of the endosomal membrane and subsequent plasmid release into the cytoplasm.

20 Phagocytosed particles lacking lipofectin are degraded in the endosomes. Particles lacking the integrin-targeting moiety are less efficient at cell binding and internalisation. Both lipofectin and the oligolysine ( $[K]_{16}$ ) element of the oligolysine-peptides probably contribute to the overall efficiency 25 of the LID complexes but the integrin-targeting capacity of the oligolysine/peptide component appears to be important for optimal targeting and internalisation of the complexes.

The present invention also relates to the use of the modified 30 spacer element of the integrin-binding component in another transfection complex. As indicated above, WO96/15811 described a transfection complex that comprises an integrin-binding component, a nucleic acid binding component and a nucleic acid, that is to say, it describes a complex analogous to the LID 35 complex described above, but lacking the lipid component. We have found, as described above, that the inclusion of the lipid

component greatly improves the transfection efficiency. However, there maybe circumstances when the increased levels of transfection that result from the use of an improved spacer element as described herein may give transfection levels that are sufficient even in the absence of the lipid component.

Accordingly, the present invention also provides a complex that comprises

- (i) a nucleic acid, especially a nucleic acid encoding a sequence of interest,
- 10 (ii) an integrin-binding component, and
- (iii) a polycationic nucleic acid-binding component, in which complex the integrin binding component comprises an integrin-binding element and a spacer element, the spacer element being longer and/or more hydrophobic than the dipeptide spacers GG (glycine-glycine) and GA (glycine-alanine).

The various components of the complex are as described above for the lipid-containing complex. The invention also provides 20 all the various other embodiments described above in relation to the lipid containing complex when modified by the omission of the lipid component.

It is known that transfection efficiency of confluent and other 25 slowly dividing and non-dividing cells is very low, particularly when receptor targeted vectors are used. We have now found that transfection of confluent and other slowly dividing and non-dividing cells that are in contact with each other using an integrin-targeted vector may be greatly 30 increased when the cells are also treated with an agent that disrupts cell-cell junctions.

We found that transfection efficiency of airway epithelial cells *in vitro* using two different reporter genes was increased 35 about four-fold, and *in vivo* transfection of mouse lungs was also increased about four-fold.

The observation is particularly surprising in view of the fact that calcium ions have previously been shown to be important for transfection using polycationic vectors and, furthermore, 5 the fact that the cells were not mitotic. The use of the calcium-chelating agent EGTA would have been predicted, on the basis of the observations of Haberland, to reduce transfection efficiency, not to increase it. Furthermore, and independently, the problem of access of the introduced nucleic acid to the 10 nucleus still remains. The major limiting step in transfection of non-mitotic cells is considered to be delivery of the transfected nucleic acid into the nucleus. Transportation of the nucleic acid through the cytoplasm to the nucleus is slow and the pores in the nuclear envelope are too small to permit 15 rapid entry of the transfected nucleic acid. It should be noted that Wang (1998) used keratinocyte growth factor (KGF) to stimulate proliferation of differentiated epithelia treated with EGTA. No such agent was used in our investigations.

20

Accordingly, any of the embodiments of the present invention may be carried out in the presence of an agent that disrupts cell-cell junctions, that is to say, the transfection step involved in those embodiments may be carried out in the 25 presence of an agent that disrupts cell-cell junctions.

For example, the present invention also provides a method of transfecting confluent cells or other slowly dividing cells or non-dividing cells that are in contact with each other, that is 30 to say, cells that are substantially non-mitotic, with a nucleic acid, which method comprises treating the cells with a complex of the present invention and with an agent that disrupts cell-cell junctions.

35 The use of an agent that disrupts cell-cell junctions to enhance transfection, particularly of confluent cells or other

- 30 -

slowly dividing cells increases the range of cells that can be transfected efficiently, whether for use *in vitro*, for example, as a "cell factory", for subsequent use in gene therapy, or in transfections carried out *in vivo*.

5

The confluent cells or other slowly dividing cells or non-dividing cells that are in contact with each other may be in the form of a culture, for example, a confluent culture *in vitro*. Methods for producing such cultures are well known, and 10 any cells that can be grown to confluence *in vitro* may be transfected according to the present invention.

Alternatively, confluent cells or other slowly dividing cells or non-dividing cells that are in contact with each other may 15 be transfected *in vivo*. A particular example of a tissue that comprises confluent, differentiated and hence substantially non-dividing cells and that has proved recalcitrant to transfection is the airway epithelium, a target for gene therapy for cystic fibrosis and asthma. Other epithelial and 20 endothelial tissues are also particularly suitable targets for transfection according to the present invention.

The cell-cell junctions that are to be disrupted in the method of the present invention are junctions between adjacent cells. 25 The exact types of junction may vary from tissue to tissue to cell type to cell type, and the junctions include gap junctions and tight junctions. The tight junction, found in epithelia, is also known as zonula occuldens. The cell-cell junctions to be disrupted according to the present invention are not limited 30 to junctions in any specific tissue or between any particular types of cells. Examples of junctions that may be disrupted include those found in certain types of tissues *in vivo*, for example, epithelial and endothelial tissues.

35 Agents that are capable of disrupting cell-cell junctions, for example, gap junctions and tight junctions, are known, for

- 31 -

example, calcium-chelating agents and calcium-binding agents, for example, EDTA (ethylenediaminetetra-acetic acid) or, especially, EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid) (Schmid RW & Reilly CN, Analytical Chemistry 29, 264, 1957). EGTA is generally preferred as it is more specific for calcium than is EDTA. It is also better tolerated by cells, both *in vitro* and *in vivo*.

A further approach is the use of antibodies to substances involved in cell-cell adhesion, for example, at gap junctions or tight junctions, for example, cadherins. Antibodies, especially monoclonal antibodies, to such substances, for example, anti-cadherins, may be used as an agent capable of disrupting cell-cell junctions.

15

The cells are treated with the vector of choice in the usual manner for transfection using that vector. The agent that disrupts cell-cell junctions may be used before the cells are treated with the vector but it is preferably to treat the cells with the agent and the vector at the same time or substantially the same time.

The agent that disrupts cell-cell junctions is used in amount effective to disrupt the junctions. In the case of EGTA for use *in vitro*, the concentration of EGTA is about 1mM or less, for example, from about 0.5 mM to 1 mM. Higher concentrations may be used, but care should be taken with regard to toxicity.

A concentration of about 1 mM is generally preferred for use *in vitro*. For use *in vivo* the concentration of EGTA may be about 25 mM to 200 mM, for example, 100 mM. Concentrations greater than 200 mM may be used, but again care must be taken with regard to toxicity at high concentrations, for example, 400 mM may be lethal. Concentrations of about 100 mM are generally preferred.

35

The cells may be transfected *in vitro* or *in vivo*. Transfection

in vitro is particularly useful for transfecting non-dividing cells with genes or anti-sense DNA of interest. Such cells may be harvested for use, for example, for administration to a patient or for use for protein production. Alternatively, such cells may be used in their confluent state, for example, *in situ*, as disease models for drug testing. It is considered that confluent cells, which are generally non-dividing and may be differentiated, are often better models of tissues that are sub-confluent cells. Cells may be grown to confluence in microwells, or using more sophisticated systems, for example, at an air-liquid interface. Various systems for growing confluent cells for use as models for drug testing are being developed. The ability to transfect cells in such systems is a great advantage.

15

Confluent cells and other slowly dividing or non-dividing cells that are in contact with each other, including differentiated cells, may be transfected *in vivo*. The present invention provides such a method of transfection and also provides the use of an agent that disrupts cell-cell junctions and a receptor targeted vector in the manufacture of a medicament for the transfection of cells, especially confluent, or other slowly dividing or non-dividing cells that are in contact with each other, for example, substantially non-mitotic cells.

25

Such cells include, for example, endothelial or epithelial cells, for example, cells of the any part of the airway epithelium, including bronchial and lung epithelium, and the corneal endothelium. The airway epithelium is an important target for gene therapy for cystic fibrosis and asthma.

The following non-limiting Examples illustrate the present invention. Examples 1 to 14 illustrate general techniques and/or are comparative Examples. The Examples refer to the accompanying drawings, in which:

- 33 -

Figure 1 shows the effect of different amounts of lipofectin (DOTMA:DOPE) on the enhancement of transfection of ECV304 cells using a complex consisting of lipofectin, oligolysine-peptide 1 ([K]<sub>16</sub>GACRGDMFGCA [SEQ.ID.NO.:19]) and plasmid pGL2.

5

Figure 2 shows the effect of different amounts of lipofectin on the enhancement of transfection of A375M, COS-7 and ECV-40 cells using a complex consisting of lipofectin, oligolysine-peptide 1 ([K]<sub>16</sub>GACRGDMFGCA) and plasmid pGL2.

10

Figure 3 shows the effect of the order of mixing the components of a complex consisting of lipofectin (L), oligolysine-peptide 1 ([K]<sub>16</sub>GACRGDMFGCA) [SEQ.ID.NO.:31] (I) and plasmid pGL2 (D) on the enhancement of transfection of ECV40 cells.

15

Figure 4 shows a comparison of enhancement of transfection by lipofectin of complexes containing plasmid pGL2 and oligolysine-peptide 1 ([K]<sub>16</sub>GACRGDMFGCA, [SEQ.ID.NO.:31] pep 1), or oligolysinepeptide 5 ([K]<sub>16</sub>GACDCRGDCFCA [SEQ.ID.NO.:34], pep 5), 20 or oligolysine-peptide 6 ([K]<sub>16</sub>GACRRETAWACG [SEQ.ID.NO.:35], pep 6) or [K]<sub>16</sub> (K16), with lipofectin (lip) and without lipofectin, and a complex containing plasmid pGL2 with lipofectin:[K]<sub>16</sub>lysine-peptide 1 in a ratio by weight of 4:1 (Lipo 4 to 1).

25

Figure 5 shows the dose-dependency of a complex containing lipofectin, oligolysine-peptide 6 ([K]<sub>16</sub>GACRRETAWACG) [SEQ.ID.NO.:12] and plasmid pGL2 on the availability of integrin-binding ligands.

30

Figure 6 shows the structure of various complexes, as determined using atomic force microscopy, the complexes being formed with different combinations of plasmid DNA (plasmid pGL2), oligolysine-peptide ([K]<sub>16</sub>-peptide 6) and lipofectin as follows: 35 A: [K]<sub>16</sub>-peptide 6 and plasmid pGL2; B: [K]<sub>16</sub>-peptide 6, lipofectin and plasmid pGL2; C: lipofectin and plasmid pGL2.

- 34 -

optimal ratio; D: lipofectin and plasmid pGL2, suboptimal ratio.

Figure 7 shows levels of expression of IL-12 48 hours after 5 transfection of COS-7 cells and neuroblastoma cells lines IMR-32, KELLY and SHSY-5Y with a complex containing lipofectin, oligolysine-peptide 6 ( $[K]_{16}$ GACRRETAWACG) [SEQ.ID.NO.:35] and either two retroviral plasmid constructs encoding the two domains of IL-12 (MFGS-IL12) or one plasmid containing a fusion 10 gene, Flexi-12 under a CMV promoter.

Figure 8 shows the effect of transfection with anti-sense oligonucleotides (AS) to the thrombin receptor (PAR-1) on thrombin induced proliferation of human foetal lung fibroblasts 15 (HFL-1 cells).

Figure 9 shows the effect of transfection of haematopoietic cell lines HL60, PLB985, TF1 and U937 with LID complexes containing lipofectin, the reporter gene pEGFP-N1 and either  $[K]_{16}$ -peptide 6 (pep 6) or  $[K]_{16}$ -peptide 8 (GGCRGDMFGCA [SEQ.ID.NO.:36] pep 8) compared with untreated cells. The percentage of GFP positive cells is determined using a fluorescence activated cell sorter.

25 Figure 10 shows the effect of the longer, highly hydrophobic spacer XSXGA [SEQ.ID.NO.:18] (Pep12) on transfection of primary porcine smooth muscle cells (VSMCs) compared with the same integrin-binding peptide having a GA spacer (Pep6). TFI cells are shown as shaded columns, Jurkat cells as solid columns.

30

Figure 11 shows the effect of the longer, highly hydrophobic spacer XSXGA [SEQ.ID.NO.:18] (Pep12) on transfection of Jurkat and TF1 cells compared with the same integrin-binding peptide having a GA spacer (Pep6). The black columns show the results 35 with Jurkat cells, the shaded columns the results with TF1 cells.

- 35 -

Figure 12 shows flow cytometry analysis on the transfection efficiency with pEGFP in subconfluent (A, B) and confluent (C, D) 1HAEo- cells (A, C) and 2CFSMEO- cells (B, D). High efficiency was observed in subconfluent cells but it dropped dramatically when the cells became confluent.

Figure 13 shows luminometric assay of the effects of EGTA (A, B) and anti-E-cadherin (C, D) on transfection. The confluent (A) and subconfluent (B) 1HAEo- cells were transfected with LID complexes after pre-treatment with EGTA (EGTA) or in the presence of EGTA (LID+EGTA). Significant enhancement effects were observed in confluent but not subconfluent cells with LID vector incorporated with EGTA (LID+EGTA) compared with either the EGTA pretreatment (EGTA) or the control transfection without EGTA (OptiMEM). Significant increase in transgene luciferase activities was also observed in confluent 2CFSMEO- cells (C) incubated with anti-E-Cadherin in three different concentrations compared to the transfection without antibody (labelled as LID) ( $p<0.05$ ) or in the presence of IgG controls (labelled as LID + IgG control). Again, no significant difference was observed in sub-confluent cells (D) transfected in the presence of either anti-E-Cadherin or IgG control.

Figure 14 shows flow cytometry analysis of EGTA effects on transfection efficiency (A-C) and the rate of BrdU incorporation (D-F) in confluent 1HAEo- cells. Cells were transfected with pEGFP (A) or pEGFP plus EGTA (B), or pEGFP plus EGTA and aphidicolin (C). In parallel with the transfection, cells were labelled with BrdU (D) or BrdU plus EGTA (E), or BrdU plus EGTA and aphidicolin (F). 8.6% cells expressed transgene EGFP (A). EGTA increased the efficiency to 31.7% (B) and this enhancement effect was still observed in the presence aphidicolin where the EGFP-positive cells accounted for 23.6% (C). Meanwhile, EGTA showed no effects on cell proliferation with the rate of BrdU incorporation being 7.1% in

confluent cells (D), 6.5% in the presence of EGTA (E), and 5.3% in the presence of EGTA and aphidicolin (F).

Figure 15 shows sub-confluent 1HAEo- cells: flow cytometry analysis of EGTA effects on transfection efficiency (A-C) and the rate of BrdU incorporation (D-F). Cells were treated in the same way as in the confluent cells shown in Figure 13. Transfection efficiency was as high as 44.5% in sub-confluent cells (A). Similar efficiency of 45.6% was observed in the presence of EGTA (B) and there were still 24.8% cells being transfected in the presence of aphidicolin (C). Instead of promoting proliferation, EGTA decreased BrdU incorporation rate in sub-confluent cells as the proportion of BrdU-positive cells dropped from 43.0% (D) to about 23.9% after EGTA treatment (E). 15 7.8% cells were labelled with BrdU in the presence of aphidicolin (F).

Figure 16 shows double immunofluorescence for transgene  $\beta$ -Galactosidase (transgene expression shown by green cytoplasmic staining, irregular shapes) and BrdU labelling (shown by red nuclear staining, smaller rounder shapes) in subconfluent (A) and confluent (B, C) 1HAEo- cells. Most of the subconfluent cells were labelled with BrdU and many of them expressed transgene simultaneously (irregular shape containing rounded shape), shown in Figure 15A. Only few confluent cells were positive for  $\beta$ -galactosidase while few were labelled with BrdU (B). After EGTA treatment many more cells expressed transgene see Figure 15C while their proliferation state was not affected as evident by the unchanged rate of BrdU labelling, few cells 30 were stained red.

Figure 17 shows photomicrographs of confluent 1HAEo- cells showing the effects of EGTA treatment. The images in left-hand column (A, C, E, G) shows the cells before EGTA treatment and 35 the right-hand column (B, D, F, H) are the cells after EGTA treatment. They are representative images of the typical

morphology of live confluent cells (A, B: x400, conventional inverted microscope), immunofluorescence for tight junction protein occludin (C, D: x400 projected images, confocal microscope), binding of LID complexes to cell surfaces (E, F: 5 x100, inverted confocal microscope) and the expression of transgene pEGFP (G, H: x100, conventional inverted microscope). Confluent cells form an un-permeable cell sheet (A). Tight junctions were clearly confined around cells as showed by immunofluorescence for occludin (C). This allowed only a few 10 particles of LID vectors to bind on to the cell surface (E) and only a small number of cells expressed transgene EGFP (G). After treatment with EGTA, the confluent cells rounded up (B). Tight junctions were disrupted as showed by the broken lines of immunofluorescence for occludin (D) and, much more LID complex 15 particles bound to the cell surfaces (F) and consequently, more cells expressed transgene EGFP (H).

The following non-limiting Examples illustrate the invention.

20 EXAMPLES

MATERIALS & METHODS

Cell Lines

The cell line COS-7 (monkey kidney epithelial cells) were maintained in Dulbecco's Modified Eagle Medium (DMEM; Life 25 Technologies, Paisley, U.K.) supplemented with 10 % foetal calf serum (FCS), L-glutamine, penicillin and streptomycin. ECV304 (spontaneously transformed human umbilical vein endothelial cells) were grown in 199 Medium (Life Technologies, Paisley, U.K.). HT1080 fibrosarcoma cells and A375M melanoma cells were 30 maintained in DMEM and 10% FCS. IMR2 neuroblastoma cells were grown in DMEM F12 Nutrient Mix (Life technologies). Porcine primary smooth muscle cells (VSMCs) and haematopoietic cells (Jurkat and TF1) and airway epithelial cells were grown in media suitable for those cell types, for example, human airway 35 epithelia (HAE) cells type HAE0-, were grown in Modified Eagle Medium (MEM) obtained from Life Technologies (Paisley,

Scotland) supplemented with 10% foetal calf serum and 2 mM L-glutamine.

Cell lines were all grown in a 37°C incubator with a 5% CO<sub>2</sub> water-saturated atmosphere.

#### Peptide synthesis

The sequence of peptide 6, GACRRETAWACG [SEQ.ID.NO.:12], was based on an  $\alpha$ 5 $\beta$ 1-specific peptide from a phage display library 10 (Koivunen et al., 1995). The oligolysine-peptide [K]<sub>16</sub>GACRRETAWACG [SEQ.ID.NO.:35] was synthesised as follows:

Protected amino acids and preloaded Gly-Wang resin were obtained from Calbiochem-Novabiochem (Nottingham, U.K.). 15 Solvents and HBTU [2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] were obtained from Perkin-Elmer Applied Biosystems, U.K. The peptide was synthesised on a Model 431A updated Applied Biosystems Solid Phase Synthesiser on 0.1 mmol preloaded Gly-Wang resin (Calbiochem-Novabiochem, 20 Nottingham, U.K.) using basic feedback monitoring cycles and HBTU as a coupling reagent. 9-fluorenylmethoxy-carbonyl was used for temporary  $\alpha$ -amino group protection. Side-chain protecting groups were tert-butyloxycarbonyl for Lys and Trp, trityl for Cys, 2,2,5,7,8-pentamethylchroman-6sulphonyl for 25 Arg, tert-butylester for Glu and tert-butyl ether for Thr.

Cleavage from the resin and deprotection of the peptide was achieved by treating the peptidyl-resin with 10 ml of a mixture containing 10 ml trifluoroacetic acid, 0.25 ml ethanedithiol, 0.25 ml triisopropylsilane at 20°C for two hours. The peptide 30 was precipitated using ice-cold diethylether and then filtered through a fine sintered glass filter funnel under light vacuum.

The peptide precipitate was dissolved in 10% acetic acid/water solution and freeze dried. The crude peptide was analysed by reverse phase HPLC and matrix assisted laser desorption 35 ionisation time of flight mass spectroscopy. Purity of the crude peptide was about 70% by reverse phase HPLC, and mass

- 39 -

analysis using a Finnegan LazerMat gave a molecular weight of 3331.5 for the  $\text{MH}^+$  ion which was in excellent agreement with calculated weight for  $\text{MH}^+$  ion of 3331.46.

5 Oligolysine-peptide 1:  $[\text{K}]_{16}\text{GACRGDMFGCA}$  [SEQ.ID.NO.:31] and oligolysine-peptide 5:  $[\text{K}]_{16}\text{GACDCRGDCFCA}$  [SEQ.ID.NO.:34] were obtained from Zinsser Analytic (Maidenhead, U.K.).

Oligolysine-peptide 66:  $[\text{K}]_{16}\text{GACATRWARECG}$  [SEQ.ID.NO.:28] and 10 oligolysine-peptide 12:  $[\text{K}]_{16}\text{XSXGACRETAWACG}$  [SEQ.ID.NO.:29] may be synthesised as described above for oligolysine-peptide 6 or obtained from Zinsser Analytic.

#### Plasmid DNA

15 The plasmids pGL2, which contains a luciferase reporter gene (Promega, Madison, WI, U.S.A.) and pCMV $\beta$ , which contains a  $\beta$ -galactosidase reporter gene (Clontech, Palo Alto, California, U.S.A.) were grown in *Escherichia coli* DH5a and purified, after bacterial alkaline lysis, on Qiagen resin columns (Qiagen Ltd., 20 Crawley, U.K.) by the manufacturer's instructions.

Isopropanol-precipitated DNA pellets were washed with 70% ethanol then dissolved in water or TE buffer (10 mM Tris-Cl, pH 8.0 and 1 mM EDTA).

25 Spectrophotometric measurements of plasmid solutions were used to assess plasmid concentration ( $A_{260}$ ) and purity ( $A_{260}/A_{280}$  ratio). Plasmid solutions were adjusted to a concentration of 1 mg/ml and stored at 4°C.

#### 30 Formation of transfection complexes

Cells were seeded into 24-well plates at  $5 \times 10^4$  cells per well then incubated overnight at 37°C in complete growth medium. The following day, transfection complexes were made from the following stock solutions, all prepared in OptiMEM (Life 35 Technologies, Paisley, U. K.), lipofectin (an equimolar mixture of the cationic lipid N-[1-(2,3-dioleyloxy)propyl]-N,N,N-tri-

- 40 -

methylammonium chloride (DOTMA) and the neutral lipid dioleoyl phosphatidylethanolamine (DOPE), obtained as "Lipofectin" from Life Technologies, Paisley, U.K.) (1 mg /ml), pGL2-control (1 mg/100 ml) and [K]<sub>16</sub>/integrin-targeting peptide 1, 5 or 6 (0.1 5 mg/ml).

Complexes were made usually with three components: oligolysine-peptide (I), plasmid DNA or RNA (D) and lipofectin (L), by mixing together the different components with an automatic 10 pipette. The mixture LID was made in the same way in the optimal weight ratio 0.75:4:1 (L:I:D). Both types of mixture were left to aggregate for at least 30 min then diluted to a concentration of one microgram DNA per 0.5 ml with OptiMEM. The growth medium was removed from each well then 0.5 ml of 15 transfection complex added. The plate was then returned to the incubator for four to six hours. The transfection medium was then removed and replaced with 1 ml of complete growth medium. Transfected cells were incubated for 48 to 72 hours then assayed for reporter gene activity.

20

#### Luciferase assays

Cells transformed with pGL2 were washed twice with PBS to remove serum then 100 microlitres of Reporter Lysis Buffer (Promega, Madison, WI, U.S.A.) was added to each well and 25 placed at 40°C for 15 to 30 minutes. Cells were then dislodged by scraping with a yellow micropipette tip. Cellfree lysates were then prepared and assayed with a Luciferase Assay kit (Promega, Madison, WI, U.S.A.) following the manufacturer's instructions. Total light emission was measured for 60 seconds 30 on an LKB 1251 Luminometer (Labtech, Uckfield, U.K.). The protein concentration of each sample was then determined with Protein Assay Reagent (BioRad, Hercules, CA, U.S.A.) and luciferase enzyme activity expressed in terms of relative light units per milligram of protein (RLU/mg).

35

#### LacZ assays

- 41 -

$\beta$ -galactosidase activity was detected by staining with X-gal. After washing with PBS cells were fixed to the plastic plates by addition of 0.5% glutaraldehyde in PBS for 20 minutes at 40°C. Wells were washed with PBS and cells were stained with 5 X-gal at 37°C for up to six hours.

Atomic Forces Microscopy (AFM)

Atomic forces microscope analysis of transfection complexes was performed as described previously (Wolfert & Seymour, 1996) 10 using an AFM-2, part of the NanoScope II (Digital Instruments, Santa, Barbara, U.S.A.). Transfection complexes of [K]<sub>16</sub>-peptide 6/pGL2, with and without lipofectin, were prepared as described above except that water was used as the diluent for all components rather than OptiMEM.

15

**Example 1: Effect of different amounts of lipofectin (DOTMA/DOPE) on transfection**

Transfection complexes were prepared as described above in the Materials & Methods section. The complexes were made by 20 mixing solutions of oligolysine-peptide 1 ([K]<sub>16</sub>GACRGDMFGCA) [SEQ.ID.NO.:31] at 0.1 mg/ml in OptiMEM low serum tissue culture medium with a solution of lipofectin (DOTMA/DOPE cationic liposome as above) in a range of concentrations from 1 to 10  $\mu$ g/100  $\mu$ l in OptiMEM. Finally, the appropriate amount of 25 pGL2-control plasmid DNA (0.1 mg/ml) was added and mixed by repeated pipetting. The ratio of mixing of each component was a constant 4  $\mu$ g of oligolysine-peptide per  $\mu$ g of DNA, while the proportion of lipofectin varied from 1 to 10  $\mu$ g per  $\mu$ g of DNA. ECV304 cells were transfected with the complexes as described 30 above, incubated for 48 hours then assayed for luciferase expression as described above. The results are shown in Figure 1.

Complexes formed with 1  $\mu$ g of lipofectin and 4  $\mu$ g of oligo- 35 lysine-peptide per microgram of plasmid were almost 100-fold more active than complexes lacking lipofectin. Addition of

- 42 -

larger amounts of lipofectin reduced transfection activity in a lipofectin dose-dependent manner.

Similar results were obtained with  $[K]_{16}$ -peptide 6  
5 [SEQ.ID.NO.:35].

**Example 2: Effect of different amounts of lipofectin on transformation in three different cell lines**

Experiments were then performed to refine the optimal amount of 10 lipofectin in LID transfection complexes using three different cell lines A375M (melanoma cells), COS-7 (monkey kidney epithelial cells) and ECV304 (human umbilical cord endothelial cells).

15 Transfection complexes were made as described in Example 1 but using a narrower range of amounts of lipofectin. Lipofectin/- oligolysine-peptide/DNA complexes were prepared with constant amounts of  $[K]_{16}$ -peptide 1 ( $[K]_{16}$ GACRGDMFGCA) [SEQ.ID.NO.:31] (4  $\mu$ g) and pGL2 (1  $\mu$ g) plasmid DNA and a range of lipofectin 20 amounts (1 to 2.5 micrograms). Complexes were used to transfect A375M, COS-7 and ECV304 cells, which were then harvested two days later for luciferase expression analysis.

The results are shown in Figure 2. In each case the optimal 25 transfection ratio peaked at 0.75  $\mu$ g of lipofectin per microgram of plasmid DNA. This combination of the amounts of the components was maintained in all subsequent examples.

A mixing ratio L:I:D of 0.75:4:1 by weight corresponds to a 30 molar ratio of 0.5 nmol lipofectin: 1.25 nmol oligolysine-peptide 1: 0.25 pmol pGL2-control. The molar charge of each component is 0.5 moles positive charge per mole lipofectin, seventeen moles positive charge per mole  $[K]_{16}$ -peptide 1 and 12,000 moles negative charge per mole of pGL2 (6 kb). Therefore, in the optimal transfection complex, 3 nmol of negative 35 charge from the plasmid is mixed with 21 nmol of positive charge.

charge from oligolysine-peptide 1 and 0.25 nmol positive charge from lipofectin. Hence the charge ratio of approximately 7:1 positive to negative charges in LID complexes is little altered by the incorporation of 0.25 nmol positive charge from lipofectin into high efficiency LID transfection complexes. It is likely, therefore, that the improvement in transfection efficiency of LID complexes is not charge related.

**Example 3: Effect of the order in which the components of the complex are mixed.**

To determine the procedure for the production of optimal LID transfection complexes transfections were performed with complexes made by adding the components of the complexes in different orders. All combinations were prepared with the same amounts and concentrations of the components (1  $\mu$ g pGL2 plasmid DNA, 0.75  $\mu$ g of lipofectin and 4  $\mu$ g of oligolysine-peptide 1 ( $[K]_{16}$ GACRGDMFGCA)). Transfections were performed in ECV304 cells and luciferase activity was assessed as described above.

20

The results are shown in Figure 3 in which D represents the plasmid vector pGL2, I represents  $[K]_{16}$ -peptide 1 and L represents lipofectin. The expression data indicates that the order of mixing LID was optimal. Significantly, combinations in which the lipofectin was the last component added were least efficient. The order of mixing, LID, was employed in all subsequent transfection experiments.

**Example 4: Transfection rates**

30 Cells were transfected with optimised oligolysine-peptide/lipofectin/pCMV $\beta$  complexes as described in Examples 1 and 2 prepared in the order of mixing LID but using pCMV $\beta$  as the plasmid vector (component D) instead of pGL2. The cells were stained for  $\beta$ -galactosidase activity with X-gal as described above. A 35 number of cell types, A375M, COS-7 and ECV304 displayed transfection efficiencies of 50 to 100% compared to 1 to 10%

achieved with oligolysine-peptide/DNA complexes alone. This represents a very significant improvement in transfection efficiency.

5 Example 5: Comparison of enhancement with lipofectin and with different oligolysine-peptides

To compare the effect of different integrin-targeting oligolysine-peptides, duplicate sets of complexes were formed with plasmid pGL2 and one of the following:

10 oligolysine-peptide 1 ([K]<sub>16</sub>GACRGDMFGCA, pep 1) [SEQ.ID.NO.:31],  
oligolysine-peptide 5 ([K]<sub>16</sub>GACDCRGDCFCA, pep 5)  
[SEQ.ID.NO.:34], oligolysine-peptide 6 ([K]<sub>16</sub>GACRRETAWACG, pep  
6) [SEQ.ID.NO.:35, and [K]<sub>16</sub> [SEQ.ID.NO.:30].

One set of complexes also contained lipofectin (lip), the other  
15 was without lipofectin. A control complex containing plasmid  
pGL2 with lipofectin and [K]<sub>16</sub>lysine-peptide 1 in a ratio by  
weight of 4:1 was prepared.

Each complex was used to transfect cell lines and luciferase  
20 expression determined. Complexes were made with (lip) and  
without lipofectin. An optimised complex was performed for  
comparison. All oligolysine-peptides were mixed with lipofectin and plasmid DNA (KLD) in the same optimised charge  
ratios and order of mixing.

25

The results are shown in Figure 4. Although KLD complexes were usually better transfection agents than KD or LD complexes, LID complexes generated luciferase expression levels three to six-fold higher than KLD complexes. Expression levels from LID  
30 complexes containing oligolysine-peptide 5 were two-fold lower than those containing oligolysine-peptide 1 or oligolysine-peptide 6, which may reflect the differing integrin receptor affinities of the peptides. The transfection enhancement of the LID complexes was observed with all the peptides tested, 35 two of which (peptides 1 and 5) contain the conserved RGD sequence, one of which (peptide 6) does not.

**Example 6: Specificity**

To demonstrate integrin specificity, LID complexes were prepared with constant amounts of plasmid pGL2-control and 5 lipofectin, and a range of combinations of  $[K]_{16}$ -peptide 6 and  $[K]_{16}$ . A total of 40 $\mu$ g of  $[K]_{16}$ -peptide was used, consisting of 1, 5, 10, 20, 35, 39  $\mu$ g of  $[K]_{16}$ -peptide 6 made up to 40 $\mu$ g with  $[K]_{16}$ .

10 Transfections were performed as described in Example 1 and luciferase assays performed after 48 hours. The results are shown in Figure 5. Transfection efficiency demonstrated an apparently exponential increase with increasing amounts of oligolysine-peptide 6, and, therefore, a dose-dependent 15 response to the amount of available integrin-binding ligands. Accordingly, while both the sixteen-lysine domain, and the lipofectin components are themselves capable of mediating transfection, both individually and in  $[K]_{16}$ /lipofectin combination complexes, the highest efficiency transfection is 20 directly proportional to the amount of available integrin-binding ligand.

**Example 7: Atomic force microscopy**

Atomic force microscopy experiments were performed to determine 25 and compare the structures formed by mixing 4  $\mu$ g  $[K]_{16}$ -peptide 6 and 1  $\mu$ g pGL2-control plasmid DNA (ID complexes). LID complexes were formed from  $[K]_{16}$ -peptide 6 (4  $\mu$ g)/lipofectin (0.75  $\mu$ g)/DNA (1  $\mu$ g) in the order LID which was shown to yield optimal 30 transfection results. Lipofectin/DNA complexes (LD) were formed at two different ratios; an optimal transfection ratio of 5  $\mu$ g lipofectin per microgram of pGL2 and the same ratio as used in LID complexes, 0.75  $\mu$ g lipofectin per microgram of plasmid.

The results are shown in Figure 6. ID complexes, composed of 35 oligolysine-peptide 6 and plasmid DNA, were examined initially by AFM within fifteen minutes of mixing the two components. The

complexes formed particles of low polydispersity which, on the mica coverslips, had a diameter of approximately 200 nm. A computer-generated contour map revealed that the particles formed were of irregular conical shape. LID complexes assessed by AFM formed particles of a similar size and shape to ID complexes. The additional lipofectin did not, apparently, disrupt the particles. LD complexes, however, formed at the 5:1 ratio appeared as a network of tubes with occasional particles associated with the tubes. LD complexes formed at the lower ratio (0.75:1), however, appeared to be short tubular structures. LD complexes formed at this lower ratio were inactive in transfection experiments.

LID complexes formed as above were also analysed by AFM after standing overnight. Particles were now smaller in size with diameters of approximately 50-100 nm suggesting that the particles had compacted. Computer-generated computer maps represented these particles as regular conical structures. The cones were measured and their volumes were calculated. The spheres which the particles are predicted to form when free in solution were then calculated to be 20 to 60 nm in diameter. In transfection experiments with pGL2 the compact particles formed overnight in water yielded luciferase expression results approximately twice as high as the freshly made complexes.

25

#### **Example 8: Transfection of neuroblastoma cells**

Transfection of three different human neuroblastoma cell lines, SHSY-5Y, KELLY and IMR-32 and one mouse neuroblastoma cell line, Nb2A, was optimised using an LID complex containing [K]<sub>16</sub>-peptide 6, lipofectin and either luciferase or GFP as reporter gene, as described in the Materials and Methods section and the Examples above.

The three human neuroblastoma cell lines and COS-7 cells were then transfected using the same LID complex with, instead of the reporter gene, one of two different IL-12 expressing

vectors. One vector expresses a fusion protein of the two chains of IL-12, p35 and p40, (Flexi-12; Anderson et al. 1997)

This fusion is regulated by a CMV promoter. The second IL-12 expression system consists of two retroviral constructs MFGS-5 p35 and MFGS-p40, which are retroviral plasmid constructs encoding the two separate chains of interleukin-12 (IL-12). Both genes are regulated by the retroviral long terminal repeats (LTRs). The vectors were obtained from Professor Mary Collins, UCL, London.

10

Secreted IL-12 expression was monitored by ELISA 48 hours after transfection. The transfected cells were found to secrete high levels of the cytokine, see Figure 7. The Flexi-12 construct was most efficient.

15

These results demonstrate that the transfection system of the present invention is suitable for use in a vaccine for neuroblastoma, an important childhood malignancy, and also for vaccines against other cancers.

20

**Example 9: Transfections of primary smooth muscle cells and cardiac myocytes**

Tissue cultures of rat primary smooth muscle cells (aortic smooth muscle cells) and cardiac myocytes were prepared according to standard methods (Blank et al. 1988). An LID 25 complex comprising lipofectin, [K]<sub>16</sub>-peptide 6 and GFP as a reporter gene in the optimal LID ratio and mixing order was prepared as described in the Materials and Methods section and the Examples above. The tissue cultures were transfected with 30 the LID complex as described in the Material and Methods section above. Fluorescing imaging of GFP-expressing cells demonstrates transfection efficiency in excess of 50%.

Primary smooth muscle cells and cardiac myocytes are particularly 35 resistant to plasmid-mediated transfection using most other non-viral vectors. In contrast, the transfection complex

of the present invention achieved transfection efficiencies in excess of 50%, thus demonstrating the utility of the complexes for treatment of diseases affecting muscle, including smooth muscle and cardiac muscle.

5

**Example 10: Transfections with high molecular weight constructs**  
Different size constructs can be delivered with the transfection complex of the present invention. A fibroblast culture was transfected as described in the Materials and 10 Methods section with an LID complex comprising [K]<sub>16</sub>-peptide 6, lipofectin and a 130 kB DNA construct. The complex, comprising the LID components in the optimal ratio and mixing order, was prepared as described in the Methods and Materials section and Examples above. Transfection was achieved with 2-3% efficiency.

15

Cellular process associated with the enhanced integrin-mediated internalisation of DNA using a complex of the present invention are more closely related to phagocytosis than endocytosis and are thus particularly suited to the delivery of complexes 20 containing very large DNA molecules.

**Example 11: Transfection with anti-sense DNA**

Thrombin stimulates proliferation of human lung fibroblasts. Thrombin-treated human lung fibroblasts (HFL-1 cells) proliferated 53% in response to thrombin. 24 hours before treatment 25 with thrombin, HFL-1 cells were treated with an LID complex comprising [K]<sub>16</sub>-peptide 6, lipofectin and a 20-mer antisense oligonucleotide directed against the thrombin receptor PAR-1 in the optimal ratio and mixing order prepared as described in the 30 Materials and Methods section and the Examples above. The antisense oligonucleotide-containing complex was in contact with the cells for 4 hours. 24 hours after the start of the treatment with the complex, treatment with thrombin was carried out.

35

The thrombin-induced proliferation was attenuated by 76% +/-

- 49 -

12% by the pre-treatment with the LID complex. Cells treated with the antisense-containing complex but not with thrombin did not proliferate, see Figure 8.

5 This result demonstrates the utility of the complex of the invention for efficient intracellular transport of antisense oligonucleotides, as is required for antisense therapy, for example, antiviral and anticancer therapy.

10 **Example 12: Transfection of haematopoietic cells**

Haematopoietic cells are particularly resistant to transfection with most plasmid-mediated vectors.

LID complexes were prepared as described in the Material and 15 Methods section and Examples above using lipofectin and [K]<sub>16</sub>-peptide 6, which targets  $\alpha 5\beta 1$  integrins, and pEGFP-N1 (Promega) as reporter gene. Complexes were prepared analogously substituting [K]<sub>16</sub>-peptide 8 ([K]<sub>16</sub>GACQIDSPCA [SEQ.ID.NO.:37]), which targets  $\alpha 4\beta 1$  integrins, for [K]<sub>16</sub>-peptide 6. The complexes were 20 prepared by mixing the components in the optimal ratio and mixing order as described in the Materials and Methods section and Examples above.

Four different haematopoietic cells lines (HL60, PLB985, TF1 25 and U937) were transfected as described in the Materials and Methods section with the following modifications: cells were untreated or were treated with Gm-CSF (10ng/ml) for TF1 cells or phorbol myristic acid (PMA) for the other three cells lines prior to transfection. Transfection with the LID complexes 30 containing pEGFP-N1 generated a transfection efficiency of more than 60% in all four lines as measured on fluorescent activated cell sorter, see Figure 9.

These results demonstrate the utility of the transfection 35 complex of the invention for gene therapy involving haematopoietic cells, for example, gene therapy of leukaemia

- 50 -

and bone marrow stem cell disorders. This is particularly useful because, as pointed out above, haematopoietic cells are particularly resistant to transfection with most plasmid-mediated vectors.

5

**EXAMPLE 13**

**Transfection using integrin-binding peptides having modified spacers**

10 The following oligolysine-peptides were prepared or obtained as described in the Material and Methods section:

Oligolysine-peptide 6: [K]<sub>16</sub>GACRRETAWACG [SEQ.ID.NO.:32]

Oligolysine-peptide 66: [K]<sub>16</sub>GACATRWARECG [SEQ.ID.NO.:28]

15 Oligolysine-peptide 12: [K]<sub>16</sub>XSGACRRETAWACG [SEQ.ID.NO.:29]  
[K]<sub>16</sub>: KKKKKKKKKKKKKKKKK [SEQ.ID.NO.:30]

Peptides 6 and 12 contain the same K16 and  $\alpha 5\beta 1$  integrin-targeting element (CRRETAWACG) [SEQ.ID.NO.:23]. The difference 20 between the two is that peptide 6 has the dipeptide spacer GA whereas peptide 12 has the longer, highly hydrophobic spacer XSXGA, where X is  $\epsilon$ -aminohexanoic acid. Peptide 66 is a non-integrin-binding control, which contains the oligolysine element followed by the same amino acids as in peptides 6 and 25 12, but in a scrambled order. [K]<sub>16</sub> is the oligolysine nucleic acid binding element.

Each of the oligolysine-peptides was used to form a transfection complex as described in the Materials and Methods 30 section. Luciferase was the reporter gene.

A range of cells including porcine primary smooth muscle cells (VSMCs), haematopoietic cells (Jurkat and TF1) and airway epithelial cells were tested for transfection using the 35 various complexes according to the protocols in the Material and Methods section. In all cases peptide 12, which has the

longer, highly hydrophobic spacer, performed better than peptide 6, with the GA spacer. The results obtained with the porcine primary smooth muscle cells are presented in Figure 10. The results with Jurkat and TF1 cells in Figure 11. The results obtained with the primary smooth muscle cells are particularly striking, showing an increase in transfection of about 100%.

Example 14: Transfection of confluent human airway epithelial cell in vitro in the presence of EGTA

Cell cultures

Human airway epithelial (HAE) cells, type HEAO- were seeded at 80% into 24 well plates. The cells were grown in Modified Eagle Medium (MEM) obtained from Life Technologies (Paisley, Scotland) supplemented with 10% foetal calf serum and 2 mM L-glutamine to form cultures of confluent cells. Subconfluent cultures of the same cells were also prepared.

Reporter Genes

The reporter genes used were a green fluorescent protein (GFP) reporter gene and a luciferase reporter gene. The GFP reporter gene was used in the form of plasmid pEGFP-N1, obtained from Clontech. The luciferase reporter gene was used in the form of construct pCILuc consisting of the firefly luciferase gene (Luc) inserted into the expression vector pCI (Promega, Southampton, England)

Peptide

For these *in vitro* experiments peptide 12 [K]<sub>16</sub>X SXGACRRETAWACG (X: ε amino hexanoic acid), SEQ.ID.NO.:26, was used. The oligolysine-peptide component I comprised the integrin-targeted peptide CRRETAWACG, which targets the integrin α5 receptor, with a spacer XSXGA (X: ε amino hexanoic acid), and the oligolysine [K]<sub>16</sub>, giving the sequence [K]<sub>16</sub>X SXGACRRETAWACG (Zinsser Analytic, Maidenhead, UK), see Example Transfection

vector/EGTA complexes

Transfection vector complexes were prepared as described in the Material and Methods section, see also Example 15. The complexes were prepared using 4  $\mu$ g of the peptide, 0.75  $\mu$ g of lipofectin and 1  $\mu$ g of the reporter gene. All components and the vector complex were made up in OptiMEM (Life Technologies, Inc.). EGTA (Sigma) at a concentration of 100 mM in water was added to the transfection vector complex preparation at one hundredth of the volume of the vector complex, giving a final EGTA concentration of 1 mM.

Transfection

The EGTA/vector complex mixture was added to the cultures, which were then harvested two days later. As controls, cultures were treated with OptiMEM medium alone and with the transfection vector complex without EGTA.

To investigate whether mitosis affected the results, transfection was carried out in the presence of aphidicolin, which inhibits DNA polymerase- $\alpha$ , which prevents transition of the cells from G1 to S phase. To arrest cell division Aphidicolin (Sigma, Poole, Dorset, England), was added to the cell cultures at a concentration in the range of 1 to 20  $\mu$ g/ml 24 hours prior to transfection and was maintained throughout the rest of the experiment until the cells were harvested.

Transfection levels using the luciferase reporter gene was measured as described in the Material and methods section. In the case of the GFP reporter gene, after harvesting the cells were analysed by fluorescence activated cell sorting (FACS) for quantification of the number of fluorescent cells.

The results obtained using the GFP reporter gene are presented in Table 2 below:

TABLE 2

Transfection agent(s)	Sub-confluent cells	Confluent cells
5		
Control (no vector)	0.3%	0.7%
Vector, no added EGTA	44.6%	8.9%
Vector plus EGTA	45.7%	32.4%
Vector, EGTA, aphidicolin	24.8%	24.4%

10

Figure 10 shows clearly the influence of EGTA in the increase in the number of fluorescent cells transfected with the vector in the presence of EGTA (Figure 10B) compared with the 15 vector alone, as shown in (Figure 10A).

These results show that while the transfection vector complex transfects sub-confluent cells effectively, the transfection efficiency of confluent cells is very low. However, the 20 presence of EGTA increases the transfection levels of the confluent cells four-fold, while having no effect on the efficiency of transfection of sub-confluent cells.

Bromodeoxyuridine (BrdU) labelling enables assessment of cell 25 proliferation. BrdU kits are available from Zymed Laboratories, Inc., South San Francisco, California, U.S.A.. BrdU was added to the cells at the same time as the transfection reagent and was maintained throughout the rest of the experiment until cell harvesting. The results of BrdU 30 labelling of sub-confluent and confluent HAE cells is given in Table 3 below.

TABLE 3

35

	Sub-confluent cells	Confluent cells
--	---------------------	-----------------

- 54 -

Control	0.7%	0.5%
BrdU	44.4%	7.1%
BrdU plus EGTA	25.1%	6.5%
BrdU plus aphidicolin	1.3%	5.3%

5

These results, and those shown in Table 2 for transfection in the presence of aphidicolin, demonstrate that neither the treatment with EGTA nor the transfection process itself increases the rate of mitosis in the confluent HAE cells.

10

We obtained essentially the same results using the luciferase reporter gene instead of GFP. Transfections were carried out using the transfection vector prepared as described above with the construct pCILuc, with and without EGTA, as described 15 above. Luciferase assays were performed on cell-free extracts of harvested cells using a kit obtained from Promega using an Anthos Lucy 1 Luminometer. As with the GFP experiments, luciferase levels were enhanced approximately four-fold in confluent cells treated with EGTA compared with transfections 20 performed without EGTA.

The finding that the presence of EGTA enhances transfection efficiency in the absence of mitosis is contrary to previous teachings, that mitosis is necessary for effective 25 transfection.

Previous reports of *in vitro* transfection using a viral vector and EGTA showed that pre-incubation with EGTA (for 20 minutes) was required before the addition of vector (Wang, 1998). We 30 found that pre-incubation of the cells with EGTA before transfection with the integrin-targeted transfection vector complex was no better than the results without EGTA. We found the best results were when the EGTA and the vector were admixed before application to the cells.

35

A further difference from previously reported results (Wang,

1998) is that Wang described the use of EGTA with hypotonic solutions such as water, which are themselves known to promote the disruption of tight cell junctions. We found the use of the isotonic buffer OptiMEM to be successful.

5

We also observed enhancement of transfection *in vitro* in confluent HAE cells when anti-cadherin IgG was used instead of EGTA with the transfection vector complex described above. The anti-cadherin IgG was obtained from Serotec and applied at 50  $\mu$ g/ml one hour before addition of the vector. This led to a 5 to 10 fold enhancement of luciferase activity in confluent cells whereas subconfluent cells showed no enhancement. These results confirm our theory that the enhancement results from increased availability of receptors and that, surprisingly, 15 cell division is not required.

#### EXAMPLE 15

#### METHODS AND MATERIALS

##### Airway epithelial cells

20 Human airway epithelial cell lines, a normal cell line 1HAEo- and a CF cell line 2CFSMEO-, were used in this study. 2CFSMEO- cells are immortalised, SV-40 T antigen transformed cells obtained from Dr D. Gruenert, UCSF. The 1HAEo- cells retain the morphologic and functional characteristics of epithelial cells 25 and have been used in many different studies, see (Boussat et al (2000), Cozens et al (1992a). The 2CFSMEO- cells are ΔF508 heterozygous submucosal epithelial cells, see (Canonico et al (1996), Cozens et al (1996). Both cell lines were maintained in a humidified atmosphere of 95% air and 5% CO<sub>2</sub> at 37°C in Eagle's 30 minimum essential medium (MEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100  $\mu$ g/ml streptomycin (Sigma, Poole, UK) in 75cm<sup>2</sup> culture flasks. Cells were seeded on transwell inserts of 0.4  $\mu$ m pore size and 12 mm diameter (Costar, Bucks, UK) at a density of 10<sup>5</sup> 35 cells/0.5ml/insert and were left to grow until fully confluent in about 3 days. The apical medium was then removed and growth

medium was added basolateraly to leave the cells growing at an air-liquid interface. Confluent cells were grown for further 10-14 days and were monitored with an ohmmeter (EVOM; World Precision Instruments, Stevenage, UK) until the transepithelial resistance was greater than 300  $\Omega$ .cm before transfection. For immunofluorescence studies, the cells were seeded on coverslips in 24-well plates at a density of  $10^5$  cells/ml/well and were left to grow for about 10-14 days until fully confluent. The state of confluence and development of tight junctions were also determined by the immunofluorescent detection of occludin, the structural and functional component of tight junctions (detailed below). Sub-confluent, proliferating cells were prepared by growing the cells for less then 3 days in growth medium prior to transfection.

15

#### *Plasmid DNA*

Three different plasmid DNA controls were used in this study. Plasmid pCI-Lux was prepared by subcloning a luciferase gene from pGL3 control (Life Technologies, Paisley, UK) into the eukaryotic expression vector pCI (Promega, Southampton, UK). Plasmid pCIK-LacZ, containing cytoplasm-located bacterial  $\beta$ -Galactosidase gene, was obtained from Dr. Steve Hyde (Oxford). The plasmid pEGFP was commercially available (CLONTECH Laboratories UK Ltd., Hampshire, UK). All of these genes were driven by CMV promoter. The plasmids were amplified in *Escherichia coli* DH5 $\alpha$ , lysed with alkaline and prepared using an endotoxin-free kit (Qiagen, Crawley, UK). The DNA was washed with 70% ethanol and dissolved in water. The concentration of DNA was spectrophotometrically determined by its absorbance at  $A_{260}$  and the purity was assessed with the ratio of  $A_{260}/A_{280}$ .

#### *In vitro transfection of the cells*

The transfection vector complexes called "LID complexes" and "LID vectors" hereafter, were prepared in a procedure similar to that described in Example 1. Briefly, stock solutions of the three components of the LID vector complex were prepared first.

Plasmid DNA (component D) was diluted in cell culture medium OptiMEM (Life Technologies, Paisley, UK) at a concentration of 0.01 µg/µl. The oligolysine-peptide component I comprised the integrin-targeted peptide CRRETAWACG, which targets the 5 integrin α5 receptor, with a spacer XSXGA (X: ε amino hexanoic acid), and the oligolysine [K]<sub>16</sub>, giving the sequence [K]<sub>16</sub>XSXGACRRETAWACG (Zinsser Analytic, Maidenhead, UK). The peptide component I was dissolved in Opti-MEM at 0.1 mg/ml. The lipid component L was Lipofectin, a commercially available 10 equimolar mixture of the cationic lipid N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA) and the neutral lipid dioleoyl phosphatidylethanolamine (DOPE), (Life Technologies, Paisley, UK) and was used from purchase at 1 mg/ml. Complexes were made by gentle mixing of the three 15 components: lipofectin (L), peptide (I) and DNA (D), in the optimised weight ratio of 0.75:1.94:1 (L:I:D) which corresponds to a +/- charge ratio of about 3:1. The complexes were then left 30 minutes at room temperature before being diluted to a final concentration of 1µg of DNA in 0.3 ml of Opti-MEM in 20 transwells, or in 0.5 ml for 24-well plate. The cells were incubated with the complexes for 4 hours at 37°C followed further culture in growth medium for 24 to 48 hours before being harvested for the assay of transgene expression.

#### 25 Enhancement of transfection

To enhance the efficiency of transfection in confluent epithelial cells, several agents were tested including EGTA (Sigma, Poole, UK), trypsin/EDTA (Sigma, Poole, UK), water, and mouse anti human E-cadherin antibody (Serotec Ltd, Oxford, UK). 30 It was carried out firstly by comparing the effects of pretreatment of the cells with EGTA, water and Trypsin/EDTA with EGTA formulated into LID vector without pretreatment. Confluent cells were pre-incubated for 20-30 minutes at 37°C with 2 mM EGTA, 0.05 g of trypsin/litre-0.02 g/litre of EDTA, 35 water, PBS or OptiMEM as control, respectively. Cells were then washed twice with OptiMEM and transfected with LID complexes or

LID formulated with EGTA (detailed below) for 4 hours as described above. To test the effects of anti-E-cadherin on transfection, confluent cells were pre-incubated with the antibody at increased concentrations of 2, 10 and 50  $\mu$ g/ml for 5 60 minutes at 4°C, followed by 4-hour transfection with LID complexes in the presence of anti-E-cadherin of same concentrations or mouse IgG as a control, respectively.

Most of the enhancement experiments were carried out using the 10 EGTA-formulation protocol (LID+EGTA), in which, EGTA was added to the OptiMEM containing LID complexes, at a final concentration of 2 mM. OptiMEM contains 0.9 mM CaCl<sub>2</sub> which is of half the level of conventional mediums. EGTA was first dissolved in PBS (pH7.3) to make a stock solution of 200 mM. 15 After preparing the LID complexes, EGTA stock solution was added to the complexes to achieve a final concentration of 2 mM. The transfection incubation was performed in the presence of EGTA but was replaced with complete growth medium after 4 hours. Effects of EGTA on cell junctions were monitored by 20 measuring the transepithelial resistance which dropped as early as about 10 minutes after exposure to EGTA and recovered at about 16-18 hours after removal of EGTA (data not shown).

#### *Luminometric assay for luciferase*

25 Twenty-four hours after transfection with pCI-luciferase, cells were washed with PBS, lysed by adding 100  $\mu$ l of Reporter Lysis Buffer (Promega, Southampton, UK) and detached from the plate by manual scraping using micropipette tips. Cell-free lysates were prepared by centrifugation at 2000 rpm for 5 minutes at 30 4°C. The activity of luciferase was assayed with a luciferase assay kit (Promega, Southampton, UK) on a Lucy-1 plate-reading luminometer (Anthos, Salzburg, Austria). The protein concentration of each sample was determined with Protein Assay Reagent (BioRad Laboratories, Hertfordshire, UK) by measuring 35 absorbance at 595 nm and the specific activity of luciferase was expressed as relative light unit per milligram protein

- 59 -

(RLU/mg protein).

*Transfection efficiency by flow cytometry analysis of green fluorescent protein:*

5 Cells transfected with pEGFP were washed twice with PBS, harvested by digesting with trypsin-EDTA and fixed in 4% paraformaldehyde. The cells were then analysed by fluorescence-activated cell sorting (FACS) with a FACS sorter EPICS XL (Beckman Coulter Inc, Buckinghamshire, UK). Fluorescence for 10 EGFP was measured at wavelength of 525±20 nm. Ten thousand cells were examined for the percentage of EGFP-positive cells by determining the percentage of highly fluorescent cells and subtracting the fluorescence of the untransfected control cells.

15

*Assay of cell proliferation*

Cell proliferation was assessed by incorporating 5-Bromo-2'-deoxy-uridine (BrdU) into cellular DNA detected by immunofluorescent staining using a monoclonal antibody. A BrdU 20 Labelling and Detection Kit (Roche, Basel, Switzerland) was used, which contains the BrdU labelling reagent and the monoclonal mouse anti-BrdU. While the confluent cells were transfected with EGTA-formulated LID containing pEGFP for analysis of transfection efficiency, a control group was 25 transfected with the same protocol but with 10 µM BrdU in the transfection medium for analysis of cell proliferation. Cells were maintained in the presence of BrdU throughout the 4 hour transfection incubation and for the following 24 hours incubation to label all cells that replicate during the 30 transfection period. The BrdU-treated cells were then washed with PBS, harvested with trypsin/EDTA and fixed in 70% ethanol in 50 mM glycine buffer, pH 2.0, for 30 minutes at -20°C. The primary antibody, mouse anti-BrdU diluted 1:10 with incubation buffer provided in the kit, was added to the cells for a 60- 35 minute incubation at 37°C. Cells were washed with PBS and incubated with a second layer antibody, Texas Red labelled

horse anti-mouse IgG (Vector Laboratories, Peterborough, UK), for 30 minutes at 37°C and then analysed by flow cytometry at the wavelength of 575±20 nm as detailed above. In some experiments, aphidicolin, a cell-proliferation inhibitor blocking the cell cycle in S-phase, was added to the cells to observe the effects on transfection efficiency. Aphidicolin was added to the growth medium (10 µg/ml) for 24 hours before transfection and maintained throughout the 4-hour transfection and the following 24 h period of incubation until the cells were harvested.

***Binding of LID vector to EGTA treated cells.***

The effects of EGTA on cell binding were determined by transfection with LID complexes prepared with fluorescein 15 (FITC) labelled peptide. Peptide-12 was labelled with FITC from a labelling kit (Calbiochem, San Diego, USA) and purified by dialyzing in PBS overnight, according to the manufacturer's instruction. The ability of FITC-conjugated peptide-12 to form complexes with plasmid DNA was determined by retardation test, 20 in which the electrophoresis migration of DNA is retarded by forming complexes with the cationic peptide as described previously (Hart et al., 1995). The confluent cells in transwells were first incubated with 2 mM EGTA in Opti-MEM for 30 minutes at 37°C to disrupt tight junctions and then cooled 25 for 20 minutes at 4°C. The LID complexes prepared with FITC-labelled peptide-12 were also cooled to 4°C for binding assay. The cells were then transfected with apically added LID-FITC for 60 minutes at 4°C, at which the complexes would only bind to cell surface and no internalisation would occur, see (Chu et al 30 (1999), Cornelissen et al (1997), Im et al (1986). The surface binding of the LID complexes was further differentiated from the internalised LID by incubating the cells with 1 µg/ml crystal violet (Sigma, Poole, UK) for 10 minutes at 4°C, to quench the fluorescence of surface-bound LID complexes, see (Ma 35 et al (1997), Van Amers & Van Strijp (1994). The mean numbers

of fluorescent particles were then counted in 10 random microscope fields and comparison was made between the data obtained from EGTA- treated or untreated cells.

**5 Immunofluorescence of BrdU,  $\beta$ -galactosidase and occludin**

To observe the double fluorescence labelling, the  $\beta$ -galactosidase-transfected and BrdU-labelled (as detailed above in *Assay of cell proliferation*) cells were fixed with 70% ethanol in 50 mM glycine buffer, pH 2.0, for 30 minutes at 10 20°C. The cells were then incubated with a mixture of two primary antibodies, the rabbit anti- $\beta$ -galactosidase at 1:200 (Chemicon International Inc, Harrow, UK) and the mouse anti-BrdU at 1:10 (BrdU Labelling and Detection Kit; Roche, Basel, Switzerland), followed by incubation with a mixture of FITC-15 conjugated goat anti-rabbit IgG and texas red labelled horse anti-mouse IgG (Vector Laboratories, Peterborough, UK). Transwell inserts were then excised from the plastic holder and mounted on glass slides with aqueous mountant Vectashield (Vector Laboratories, Peterborough, UK). To observe the effects 20 of EGTA on tight junction, the EGTA-treated cells were immunostained with a rabbit polyclonal antibody against tight junction protein occludin (Zymed, San Francisco, USA) diluted 1:10 with PBS. The antibody is specific to the C-terminal 150 amino acids of human occludin and has been used in many other 25 studies, see (Jou et al (1998), Martin-Padura et al (1998)). The confluent cells on transwells were incubated with 2 mM EGTA in Opti-MEM for 30 minutes at 37°C and fixed in methanol for 20 minutes at 4°C. Washed with PBS, the cells were immunostained with anti-occludin for 60 minutes, followed by incubation with 30 a fluorescein labelled goat anti-rabbit IgG (Vector Laboratories, Peterborough, UK) for 30 minutes at 37°C. The inserts were then excised and mounted on slides with Vectashield. Images were observed and captured with an inverted fluorescence microscope (Olympus IX70, Olympus Optical Company, 35 London, UK) for transwell and a confocal microscope (Leica TCS

SP, Exton, PA, USA) for excised inserts.

All data shown are representative of at least 3 independent experiments and triplicate cell cultures were used for s luminometry and flow cytometry analysis.

## RESULTS

### *Comparison of different agents to increase transfection efficiency*

10 All transfections of the airway epithelial cells were performed in parallel in both 1HAEo- and 2CFSMEO- cells and similar results were observed in both cell types in most of the experiments. In preliminary studies of transfection of sub-confluent cells with LID vector, GFP transgene expression was 15 observed in about 45% 1HAEo- cells (Figure 11A) and 56% 2CFSMEO- cells (Figure 11B) as determined by FACS analysis. However, fully confluent cells were much more resistant to transfection since the percentage of transgene positive cells fell to about 7% in both cell types (Figure 11C and Figure 20 11D).

The poor transfection efficiency of confluent cells could be due to 1) the lack of availability of receptors on basolateral surfaces, or 2) the low rate of cell proliferation and the 25 inability of plasmid DNA to enter the nucleus across the nuclear envelop. The first hypothesis was tested by treating the confluent epithelial cells with two agents known to disrupt cell junctions, EGTA and anti-cadherin monoclonal IgG, to augment gene transfer as reported previously for viral vectors, 30 see Wang et al J Virol (1998); 72: 9818-9826 & Walters et al (1999). In the first protocol, confluent cells were incubated with 2 mM EGTA prior to transfection followed by 2 washes with Opti-MEM then transfected with the LID vector as usual. In the second protocol, LID complexes were formulated with 2 mM EGTA 35 in the same solution (LID+EGTA) so that both vector and EGTA were added to cells simultaneously. In luciferase assays of

transfected cells the EGTA pre-treatment protocol produced no enhancement of transfection while LID+EGTA treatment showed an eight-fold increase in luciferase transgene expression over the control transfection in the complete absence of EGTA (Figure 5 12A). However, when the LID+EGTA formulation was used to transfect sub-confluent cells, there was no difference in transgene luciferase activities compared to control cells transfected without EGTA (Figure 12B). In a third experiment cells were treated with anti-E-cadherin both prior and during 10 transfection. A significant increase in transgene expression was observed in confluent cells transfected in the presence of anti-E-cadherin in a concentration-dependent manner compared to the transfection without anti-E-cadherin or with the presence of mouse IgG control (Figure 12C). No significant difference 15 was found in sub-confluent cells treated in the same way (Figure 12D).

Therefore, two agents, EGTA and anti-E-cadherin were shown to enhance LID-mediated gene transfer to confluent epithelial 20 cells while neither affected the transfection efficiency of sub-confluent cells. Since only confluent cells were affected, and both agents are known to affect the integrity of tight junctions, these results supported the hypothesis that transfection efficiency was reduced in confluent cells due to 25 the restriction of receptors to the basolateral surfaces reducing binding and subsequent vector uptake. However, this did not eliminate the possibility that EGTA treatment may affect the transfection efficiency by increasing rate of cell division. The rate of mitosis is a major factor affecting the 30 transfection efficiency of most plasmid-mediated vector systems.

#### ***Effects of EGTA on transfection and cell proliferation***

To test the hypothesis that EGTA treatment may enhance 35 transfection by promoting cellular proliferation transfections were performed in confluent and subconfluent 1HAEo- cells with

the LID+EGTA vector formulation. Transfection efficiency was determined from the percentage of cells transfected with the GFP reporter gene while the rate of proliferation was determined by immunodetection of BrdU incorporation by flow cytometry. Experiments were performed separately since a mutually compatible fixative for fluorescence analysis by flow cytometry could not be found.

Cells were transfected with pEGFP (A) or pEGFP plus EGTA (B), or 10 pEGFP plus EGTA and aphidicolin (C). In parallel with the transfection, cells were labelled with BrdU (D) or BrdU plus EGTA (E), or BrdU plus EGTA and aphidicolin (F).

Confluent cells were transfected poorly by LID in the absence 15 of EGTA, with only about 8% cells expressing the GFP transgene (Figure 13A). Transfection of confluent cells with the LID+EGTA formulation, however, increased the transfection efficiency of confluent cells almost four-fold to approximately 31% (Figure 13B). However, the rate of cell proliferation, as evident by 20 the BrdU labelling, was not affected by EGTA treatment, remaining unchanged at about 6~7% before (Figure 13D) and after (Figure 13E) EGTA treatment. In contrast, LID+EGTA transfection of subconfluent cells did not increase the transfection efficiency, with the transgene-positive cells being about 44- 25 45% in both EGTA negative (Figure 14A) and EGTA positive (Figure 14B) transfections. EGTA treatment reduced the proliferation of subconfluent cells from about 43% in EGTA negative group (Figure 14D) to about 24% in the EGTA positive group although this did not affect the transfection rate 30 (Figure 14E).

These results indicate that the formulation of the LID vector with 2mM EGTA greatly enhances transfection of confluent epithelial cells and that this enhancement does not involve 35 increased cellular proliferation. A possible explanation for these observations is that EGTA treatment enhances LID binding

and subsequent uptake by exposing receptors on basolateral surfaces and that the LID vector is then able to transfect non-dividing cells.

##### 5 LID+EGTA transfection of non-dividing cells

Experiments were performed to test the hypothesis that the LID vector transfects non-mitotic cells by transfecting 1HAEo- in the presence of BrdU and aphidicolin, a cell cycle inhibitor, see (Jiang et al Hum. Gene Ther. 1998; 9:1531-1542.). EGTA 10 enhancement of transfection was observed even in the presence of aphidicolin although the rate of cell proliferation indicated by BrdU incorporation was only 5% in confluent cells (Figure 13F) and 7% in subconfluent cells (Figure 14F). The LID+EGTA transfection rate of both confluent and subconfluent 15 cells treated with aphidicolin was almost identical at 23% for confluent cells (Figure 13C) and 24% for confluent cells (Figure 14C). These results support the transfection of confluent cells and indicate that the LID vector transfects non-dividing cells with an efficiency at least four-fold higher 20 than the rate of cell division. This data is consistent with the hypothesis that the LID vector transfects non-dividing cells.

To further test this proposal, cells were transfected with 25 LID+EGTA containing a plasmid encoding the  $\beta$ -galactosidase reporter gene in the presence of BrdU then cells were anaulysed by immunofluorescence microscopy to detect cells labelled with BrdU and expressing the reporter gene. Double immunofluorescence images of subconfluent cells transfected 30 with LID+EGTA indicated a high level of proliferation. Many of the cells expressing the  $\beta$ -galactosidase reporter gene were also positive for BrdU indicating preferential transfection of dividing cells. Such double stained cells can be seen in Figure 15A, one example is marked "g/r". However amongst the 35 confluent cells both proliferation frequency and transfection efficiency were much lower (Figure 15B). EGTA treatment of

confluent cells however, markedly increased the proportion of  $\beta$ -galactosidase-positive cells (irregularly shaped stained cells in Figure 15C, one example is marked "red"), while the proliferation rate as evident by BrdU labelling, remained low. 5 Few cells were stained red, see rounded stained cells in Figure 15C. While many transgene-positive subconfluent cells were proliferating cells as evident by the double labelling, most of the transgene expressing confluent cells were non-proliferative as they were not labelled by BrdU (Figure 15A and Figure 15C).

10

#### *LID-Binding to EGTA-treated Confluent Cells*

Since EGTA does not enhance transfection by increased cellular proliferation the enhancement of LID transfection may involve increased cell binding of the vector to exposed receptors on 15 the basolateral surfaces. This proposal was tested by investigating the binding of fluorescently-labelled LID complexes prepared with FITC-conjugated peptide. Incubation of FITC-LID complexes with cells at 4°C inhibited cellular internalisation by endocytosis and was confirmed by the 20 observation that most of the cell associated fluorescence signal was quenched by crystal violet treatment. The crystal violet quenching method allows differentiation between internalised and surface-associated fluorescent material. A marked difference in LID complex binding efficiency was 25 observed between the confluent cells transfected with and without EGTA. Only a few scattered dots representing FITC-labelled LID complexes bound to the cells without EGTA treatment (Figure 16E) while in the presence of EGTA, binding of LID particles was greatly increased (Figure 16F).

30

Exposure of receptors on basolateral surfaces of confluent cells may permit enhanced binding of the LID vector. This would require breakdown of the cellular tight junctions by 2mM EGTA in OptiMEM. Figure 16 shows photomicrographs of confluent 35 1HAEo- cells showing the effects of EGTA treatment. The images in left-hand column (A, C, E, G) shows the cells before EGTA

- 67 -

treatment and the right-hand column (B, D, F, H) are the cells after EGTA treatment. They are representative images of the typical morphology of live confluent cells (A, B: x400, conventional inverted microscope), immunofluorescence for tight junction protein occludin (c, D: x400 projected images, confocal microscope), binding of LID complexes to cell surfaces (E, F: x100, inverted confocal microscope) and the expression of transgene pEGFP (G, H: x100, conventional inverted microscope). Confluent cells grown on transwell inserts until an impermeable cell sheet was formed (Figure 16A). Tight junctions were clearly confined between cells as shown by positive immunofluorescent staining for occludin (Figure 16C). Under these conditions few LID particles were bound to the cell surface (Figure 16E) and only a small number of cells expressed transgene EGFP (Figure 15G). After treatment with EGTA, however, the confluent cells rounded up, leaving spaces between each other (Figure 16B). EGTA disrupted the tight junctions as evident by the broken lines of immunofluorescence for occludin (Figure 16D). Now, many more particles of LID complexes bind to the cell surfaces (Figure 16F) and subsequently, many more cells were transfected with EGFP (Figure 16H).

#### DISCUSSION

Many factors may affect the efficiency of gene transfer to airway epithelial cells, but the cell polarity and rate of proliferation are two of the main limiting factors. Modification of cell junctions and induction of cell proliferation has therefore been investigated with both viral and non-viral vectors (Bals et al (1999)). These results demonstrated marked enhancement of gene transfer to confluent airway epithelial cells with the nonviral LID vector after disrupting the integrity of cell junctions with EGTA, and increasing vector binding. EGTA Enhanced transfection was associated with the consequent increase in binding and enhancement of transfection was observed. More important, while a 4-fold increase in transfection efficiency was achieved the

rate of cell proliferation as shown by BrdU-labelling, remained unaffected at about 7%. In addition, when transfections were performed in the presence of aphidicolin, in confluent and subconfluent cells, transfection with the LID vector formulated with EGTA was observed in at least 23% cells in both cases which is about 3-fold higher than the transfection without EGTA. Together with the evidence obtained by double immunofluorescence that most of transgene-positive confluent cells were non-proliferative, the present results show that LID vector transfects non-proliferating airway epithelial cells with a relative high efficiency.

Confluent airway epithelial cells are almost entirely mitotically quiescent. As evident in this Example, the proliferating BrdU-labelled cells accounted for about 43% of subconfluent but only 7% in confluent cells. Reduced cell proliferation would result in a low efficiency of transfection as reported by Fasbender that cells in mitosis (BrdU positive) were much more likely to express transgene than BrdU-negative cells, see (Fasbender et al (1997) and, by Wilke that growth-arrested cells were less efficiently transfected, see (Wilke et al (1996). The present study also showed the transfection was much more inefficient in confluent cells than in sub-confluent cells (8% vs. 44%). Increasing the rate of cell proliferation, therefore, would enhance gene transfer to airway epithelial cells as observed by transfecting the freshly seeded cells (Fasbender et al (1997) or stimulating cell proliferation with a growth factor (Wang et al (1998)).

However, promotion of cell proliferation is not sufficient for efficient gene transfer to airway epithelial cells using a viral vector, see (Wang et al (1998)). Wang and co-workers reported that although the rate of division of airway epithelial cells was increased to about 50% by stimulating with keratinocyte growth factor, none of the cells were transfected when the viral vector was applied to the apical membrane and

gene transfer was observed only when the DNA was applied to the basal surface (16). Therefore, it would be critical to access the basolateral receptors for most of the current vectors to obtain efficient gene transfer. EGTA was found to be highly effective for promoting access of the LID vector to basolateral receptors, enhancing transfection efficiency with low toxicity, see (Wang et al (1998), Bals et al (1999), Chu et al (1999). In this Example, we have transfected confluent, non-proliferating airway epithelial cells with a relatively high efficiency by formulating the LID vector with EGTA and, by applying the LID vector to the apical surface.

Consistently, it has been reported that the low rate of cell proliferation limits gene transfer to airway epithelia by cationic lipid vector, see (Wilkie et al (1996). However, the majority of cells expressing transgene were not proliferative although the BrdU-positive cells are more likely to be transfected, see (Fasbender et al (1997). Matsui also reported that BrdU-positive cells were scattered throughout cell cluster whereas the transfection with liposome-DNA happened more frequently at the edge of cluster where the cells were more proliferative, see (Matsui et al (1997). In contrast, the results obtained in this Example showed that most of the confluent cells transfected with EGTA-formulated LID vectors were non-proliferating cells although many transfected subconfluent cells were proliferating cells. Taken all together, it suggested that, with the understanding that gene transfer could be facilitated by the high rate of proliferation, the state of proliferation, on the other hand, may not be a necessary factor for certain non-viral vectors to transfect certain cell types. It has previously been reported that microinjection of DNA/polyethylenimine complexes into the cytoplasm of several cell lines resulted in a higher expression of transgene compared with same amount of naked DNA, see (Palard et al (1998). Injection of DNA/polylysine complexes into cytoplasm of human fibroblasts led to a higher percentage

- 70 -

of expressing cells as compared to DNA alone, see (Zauner et al (1999)). Moreover, Vitiello suggested that polylysine might have a nuclear targeting activity as he found the co-localization of DNA and polylysine in cell nuclei by confocal microscopy, see 5 (Vitiello et al (1996)). All these data suggested that some polycations may facilitate the nuclear uptake of DNA complexes in certain cell types and explained in part the fact that lots of non-proliferating cells were transfected by our LID vector. However, this needs more intensive investigation especially in 10 vivo to gain the convinced conclusion.

In summary, the results presented in this Example confirm that the efficient gene transfer to non-proliferating human airway epithelial cells using the synthetic nonviral vector LID, with 15 adjuvant of a calcium chelator EGTA which transiently disrupted tight junctions to allow increased binding of LID complexes. No induction of cells proliferation was observed by EGTA treatment and most of transgene-positive cells were non-proliferative. This shows the ability of LID vector to transfect non- 20 proliferating cells and its use in gene therapy of human respiratory diseases.

## REFERENCES

1. Wu GY, Wu CH. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. *J Biological Chemistry* 1987;262(10):4429-4432.
- 5 2. Wagner E, Cotten M, Mechtler K, Kirlappos H, Birnstiel ML. DNA-binding transferrin conjugates as functional gene-delivery agents: Synthesis by linkage of polylysine or ethidium bromide to the transferrin carbohydrate moiety. *Bioconjugate Chemistry* 1991;2:226-231.
- 10 3. Cotten M, Lange. Transferrin-polycation-mediated introduction of DNA into human leukemic cells: Stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels. *PNAS* 1990;87:4033-4037.
4. Ferkol T, Perales JC, Eckman E, Kaetzel CS, Hanson RW, 15 Davis PB. Gene transfer into the airway epithelium of animals by targeting the polymeric immunoglobulin receptor. *J Clinical Investigation* 1995;95:493-502.
5. Curiel DT, Agarwal S, Wagner E, Cotten M. Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. 20 *PNAS* 1991;88:8850-8854.
6. Fernandez MA, Munoz-Fernandez MA, Fresno M. Involvement of  $\beta 1$  integrins in the binding and entry of Trypanosoma cruzi into human macrophages. *European J of Immunology* 1993;23:552-557.
7. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin 25  $\alpha v \beta 5$  selectively promotes adenovirus mediated cell membrane permeabilization. *J Cell Biology* 1994;127(1):257-264.
8. Bergelson JM, Shepley MP, Chan BMC, Hemler ME, Finberg RW. identification of the integrin VLA-2 as a receptor for echovirus 1. *Science* 1992;255:1718-1720.
- 30 9. Logan D, Abu-Ghazaleh R, Blakemore W, et al. Structure of a major immunogenic site on foot-and-mouth disease virus. *Nature* 1993;362:566-568.
10. Isberg RR. Discrimination between intracellular uptake and surface adhesion of bacterial pathogens. *Science* 35 1991;252:934-938.
11. Almeida EAC, Huovilla A-PJ, Sutherland AE, et al. Mouse

egg integrin  $\alpha 6\beta 1$  functions as a sperm receptor. *Cell* 1995;81:1095-1104.

12. Clements JM, Newham P, Shepherd M, et al. Identification of a key integrin-binding sequence in VCAM-1 homologous to the 5 LDV active site in fibronectin. *J Cell Science* 1994;107:2127-2135.

13. Lu X, Deadman JJ, Williams JA, Kakkar VV, Rahman S. Synthetic RGD peptides derived from the adhesive domains of snake-venom proteins: evaluation as inhibitors of platelet 10 aggregation. *Biochemistry J* 1993;296:21-24.

14. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. *Biol/Technology* 1995;13:265-270.

15. Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the  $\alpha 5\beta 1$  integrin from phage display library. *J Biological Chemistry* 1993;268(27):20205-20210.

16. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the  $\alpha 5\beta 1$  integrin from a phage display 20 library. *J Cell Biology* 1994;124(3):373-380.

17. O'Neil KT, Hoess RH, Jackson A, Ramachandran NS, Mousa A, DeGrado WF. Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library. *Proteins* 1992;14:509-515.

25 18. Healy JM, Murayama O, Maeda T, Yoshino K, Sekiguchi K, Kikuchi M. Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries. *Biochemistry* 1995;34:3948-3955.

19. Pasqualani R, Koivunen E, Ruoslahti E. A peptide isolated 30 from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. *J Cell Biology* 1995;130:1189-1196.

20. Hart SL, Knight AM, Harbottle RP, et al. Cell binding and internalization by filamentous phage displaying a cyclic 35 Arg-Gly-Asp-containing peptide. *J Biological Chemistry* 1994;269:12468-12474.

21. Hart SL, Harbottle RP, Cooper R, Miller A, Williamson R, Coutelle C. Gene delivery and expression mediated by an integrin-binding peptide. *Gen Therapy* 1995;2:552-554.

22. Wolfert MA, Seymour LW. Atomic force microscopic analysis of the influence of the molecular weight of poly(L)lysine on the size of polyelectrolyte complexes formed with DNA. *Gene Therapy* 1996;3:269-273.

23. Hart SL, Collins L, Gustaffson K, Fabre JW. Integrin mediated transfection with peptides containing arginine-glycine-aspartic acid domains. *In press* 1997.

24. Farhood H, Sebina A, Huang L. The role of dioleyl phos-phatidylethanolamine (DOPE) in cationic liposome mediated gene transfer. *Biochem Biophys Acta* 1995;1235:289-295.

25. Anderson R, MacDonald I, Corbett T, Hacking G, Lowdell MW and Prentice HG. *Human Gene Therapy* 1997;8:1125-1135.

26. Blank RS, Thompson MM and Owens GK. *Journal of Cell Biology* 1988;107:299.

27. Fasbender, A., Zabner, J., Zeiher, B. G., and Welsh, M. J. (1997). A low rate of cell proliferation and reduced DNA uptake limit cationic lipid-mediated gene transfer to primary cultures of ciliated human airway epithelia. *Gene Ther.* 4: 1173-1180.

28. Matsui, H., Johnson, L. G., Randell, S. H., and Boucher, R. C. (1997). Loss of binding and entry of liposome-DNA complexes decreases transfection efficiency in differentiated airway epithelial cells. *J.Biol.Chem.* 272: 1117-1126.

29. Bals, R., Xiao, W., Sang, N., Weiner, D. J., Meegalla, R. L., and Wilson, J. M. (1999). Transduction of well-differentiated airway epithelium by recombinant adeno-associated virus is limited by vector entry. *J.Virol.* 73: 6085-6088.

30. Walters, R. W., Grunst, T., Bergelson, J. M., Finberg, R. W., Welsh, M. J., and Zabner, J. (1999). Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. *J.Biol.Chem.* 274: 10219-10226.

31. Anderson, J. M. and Van Itallie, C. M. (1995). Tight

junctions and the molecular basis for regulation of paracellular permeability. *Am.J.Physiol.* 269: G467-G475.

32. Mitic, L. L. and Anderson, J. M. (1998). Molecular architecture of tight junctions. *Annu.Rev.Physiol.* 60: 121-142.

5 33. Takeichi, M. (1990). Cadherins: a molecular family important in selective cell-cell adhesion. *Annu.Rev.Biochem.* 59: 237-252.

34. Takeichi, M. (1991). Cadherin cell adhesion receptors as a morphogenetic regulator. *Science.* 251: 1451-1455.

10 35. Chu, Q., Tousignant, J. D., Fang, S., Jiang, C., Chen, L. H., Cheng, S. H., Scheule, R. K., and Eastman, S. J. (1999). Binding and uptake of cationic lipid:pDNA complexes by polarized airway epithelial cells. *Hum.Gene Ther.* 10: 25-36.

Boussat, S., Eddahibi, S., Coste, A., Fataccioli, V., Gouge, 15 M., Housset, B., Adnot, S., and Maitre, B. (2000). Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. *Am. J. Physiol Lung Cell Mol. Physiol.* 279: L371-L378.

37. Zens, A. L., Yezzi, M. J., Yamaya, M., Steiger, D., Wagner, 20 J. A., Garber, S. S., Chin, L., Simon, E. M., Cutting, G. R., and Gardner, P. (1992a). A transformed human epithelial cell line that retains tight junctions post crisis. *In Vitro Cell Dev.Biol.* 28A: 735-744.

38. Canonico, A. E., Brigham, K. L., Carmichael, L. C., 25 Plitman, J. D., King, G. A., Blackwell, T. R., and Christman, J. W. (1996). Plasmid-liposome transfer of the alpha 1 antitrypsin gene to cystic fibrosis bronchial epithelial cells prevents elastase-induced cell detachment and cytokine release. *Am.J.Respir.Cell Mol.Biol.* 14: 348-355.

30 39. Cozens, A. L., Yezzi, M. J., Chin, L., Simon, E. M., Finkbeiner, W. E., Wagner, J. A., and Gruenert, D. C. (1992b). Characterization of immortal cystic fibrosis tracheobronchial gland epithelial cells. *Proc.Natl.Acad.Sci.U.S.A.* 89: 5171-5175.

35 40. Cornelissen, C. N., Anderson, J. E., and Sparling, P. F. (1997). Energy-dependent changes in the gonococcal transferrin

receptor. *Mol. Microbiol.* 26: 25-35.

41. Im, J. H., Frangakis, C. J., Rogers, W. J., Puckett, S. W., Bowdon, H. R., Rackley, C. E., Meezan, E., and Kim, H. D. (1986). Energy dependent insulin binding, internalization and degradation in isolated cardiac myocytes from normal and diabetic rats. *J. Mol. Cell Cardiol.* 18: 157-168.

42. Ma, J. A., Chapman, G. V., Chen, S. L., Penny, R., and Breit, S. N. (1987). Flow cytometry with crystal violet to detect intracytoplasmic fluorescence in viable human lymphocytes. Demonstration of antibody entering living cells. *J. Immunol. Methods.* 104: 195-200.

43. Van Amersfoort, E. S. and Van Strijp, J. A. (1994). Evaluation of a flow cytometric fluorescence quenching assay of phagocytosis of sensitized sheep erythrocytes by polymorphonuclear leukocytes. *Cytometry.* 17: 294-301.

44. Jou, T. S., Schneeberger, E. E., and Nelson, W. J. (1998). Structural and functional regulation of tight junctions by RhoA and Rac1 small GTPases. *J. Cell Biol.* 142: 101-115.

45. Martin-Padura, I., Lostaglio, S., Schneemann, M., Williams, L., Romano, M., Fruscella, P., Panzeri, C., Stoppacciaro, A., Ruco, L., Villa, A., Simmons, D., and Dejana, E. (1998). Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. *J. Cell Biol.* 142: 117-127.

46. Pollard, H., Remy, J. S., Loussouarn, G., Demolombe, S., Behr, J. P., and Escande, D. (1998). Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. *J. Biol. Chem.* 273: 7507-7511.

47. Zauner, W., Brunner, S., Buschle, M., Ogris, M., and Wagner, E. (1999). Differential behaviour of lipid based and polycation based gene transfer systems in transfecting primary human fibroblasts: a potential role of polylysine in nuclear transport. *Biochim. Biophys. Acta.* 1428: 57-67.

48. Vitiello, L., Chonn, A., Wasserman, J. D., Duff, C., and Worton, R. G. (1996). Condensation of plasmid DNA with

- 76 -

polylysine improves liposome-mediated gene transfer into established and primary muscle cells. *Gene Ther.* 3: 396-404.

- 77 -

CLAIMS:

1. A complex that comprises
  - (i) a nucleic acid,
  - (ii) an integrin-binding component,
  - (iii) a polycationic nucleic acid-binding component, and
  - (iv) a lipid component, in which complex the integrin binding component comprises an integrin-binding element and a spacer element, the spacer element being longer and/or more hydrophobic than the dipeptide spacers GG (glycine-glycine) and GA (glycine-alanine).
2. A complex as claimed in claim 1, wherein the spacer element of the integrin-binding component is a peptide.
3. A complex as claimed in claim 1 or claim 2, wherein the spacer element is a dipeptide.
4. A complex as claimed in claims 1 to 3, wherein the spacer element comprises more than 2 naturally occurring or synthetic amino acids.
5. A complex as claimed in claims 1 to 4, wherein the spacer element comprises  $\epsilon$ -amino hexanoic acid,
6. A complex as claimed in claim 1, wherein the spacer element is XSXGA in which S = serine, G = glycine, A = alanine and X =  $\epsilon$ -amino hexanoic acid.
7. A complex as claimed in claims 1 to 6, wherein the spacer is at the N terminus of the integrin-binding element.
8. A complex as claimed in any one of claims 1 to 7, wherein the integrin-binding element is an integrin-binding peptide
9. A complex as claimed in claim 8, wherein the peptide con-

- 78 -

sists of or comprises all or part of the integrin-binding domain of a naturally-occurring integrin ligand.

10. A complex as claimed in any one of claims 1 to 9, wherein the integrin-binding peptide comprises the conserved amino acid sequence arginine-glycine-aspartic acid (RGD).

11. A complex as claimed in claim 5, wherein the integrin-binding peptide has two or more cysteine residues that form one or more disulphide bond(s), thereby forming a cyclic peptide.

12. A complex as claimed in claim 11, wherein the cyclic integrin-binding peptide is an RGD containing peptide having a cyclic region in which the conformational freedom of the RGD sequence is restricted.

13. A complex as claimed in claim 12, wherein the peptide consists of or comprises the sequence CRGDMFGC [SEQ.ID.NO.:5].

14. A complex as claimed in claim 13, wherein the peptide consists of or comprises the sequence CRGDMFGC, CRGDMFGCG CRGDMFGCA or CRGDMFGCA.

15. A peptide as claimed in claim 12, which peptide consists of or comprises the sequence CDCRGDCFCA.

16. A peptide as claimed in claim 8, which peptide consists of or comprises the sequence CRRETAWAC.

17. A peptide as claimed in claim 16, which consists of or comprises the sequence CRRETAWACA or CRRETAWACG [SEQ.ID.NO.:12].

18. A peptide as claimed in claim 8, which consists of or comprises the sequence GPEILDVPST, CQIDSPCA or CRRETAWACGKGACRRETAWACG.

19. A complex as claimed in any one of claims 1 to 18, wherein the nucleic acid component is or relates to a gene that is the target for gene therapy, gene vaccination or anti-sense therapy.

20. A complex as claimed in claim 19, wherein the nucleic acid comprises all or part of the coding sequence of the gene and also comprises transcriptional and/or translational control elements, and whereas the nucleic acid is optionally packed in a phage or vector.

21. A complex as claimed in any one of claims 1 to 20, wherein the nucleic acid component is DNA.

22. A complex as claimed in any one of claims 1 to 18, wherein the nucleic acid component is RNA.

23. A complex as claimed in any one of claims 1 to 22, wherein the nucleic acid-binding component has from 3 to 100 cationic monomers.

24. A complex as claimed in any one of claims 1 to 23, wherein the polycationic nucleic acid-binding component is an oligolysine.

25. A complex as claimed in claim 24, wherein the oligolysine has from 10 to 20, especially 16, 17 or 18 lysine residues.

26. A complex as claimed in any one of claims 1 to 25, wherein the lipid component is or is capable of forming a cationic liposome.

27. A complex as claimed in any one of claims 1 to 26, wherein the lipid component is or comprises one or more lipids selected from cationic lipids and lipids having membrane destabilising

- 80 -

or fusogenic properties.

28. A complex as claimed in claim 27, wherein the lipid component is or comprises the neutral lipid dioleyl phosphatidylethanolamine (DOPE) or a lipid having similar membrane destabilising or fusogenic properties.

29. A complex as claimed in claim 27 or claim 28, wherein the lipid component is or comprises the cationic lipid N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) or a lipid having similar cationic properties.

30. A complex as claimed in claim 29, wherein the lipid component is or comprises a mixture of DOPE and DOTMA, especially an equimolar mixture thereof.

31. A complex as claimed in claim 30, which comprises an equimolar mixture of DOPE and DOTMA as the lipid component, an integrin-binding peptide as the integrin-binding component, and  $[K]_{16}$  as the polycationic nucleic acid-binding component.

32. A complex as claimed in claim 30 or claim 31, wherein the ratio lipid component:integrin-binding/polycationic nucleic acid-binding component: nucleic acid is 0.75:4:1 by weight or 0.5 nmol:1.25 nmol:0.25 nmol on a molar basis.

33. A complex as claimed in any one of claims 1 to 30, wherein the lipid component is or comprises 2,3-dioleyloxy-N-[2-(spermidinecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium-trifluoridoacetate (DOSPA) or a lipid having similar properties to those of DOSPA.

34. A complex as claimed in claim 33, wherein the lipid component is or comprises a mixture of DOPE and DOSPA, especially a mixture of one part by weight DOPE to 3 parts by weight DOSPA.

- 81 -

35. A complex as claimed in claim 34, which comprises a mixture of DOPE and DOSPA as the lipid component, an integrin-binding peptide as the integrin-binding component, and  $[K]_{16}$  as the polycationic nucleic acid-binding component.

36. A complex as claimed in claim 35, wherein the ratio lipid component:polycationic nucleic acid-binding component: nucleic acid is 12:4:1 by weight.

37. A process for the production of a complex as claimed in any one of claims 1 to 36, which comprises admixing components (i), (ii), (iii) and (iv).

38. A process as claimed in claim 37, wherein the components are admixed in the following order: lipid component, integrin-binding component/polycationic nucleic acid-binding component, nucleic acid.

39. A complex as claimed in any one of claims 1 to 36, obtainable by a process as claimed in claim 37 or claim 38.

40. A mixture comprising an integrin-binding component, a polycationic nucleic acid-binding component, and a lipid component, the integrin binding component being as defined in claim 1.

41. A mixture as claimed in claim 40 wherein the integrin-binding component is as defined in any one of claims 2 to 18.

42. A mixture as claimed in claim 40 or claim 41, wherein the polycationic nucleic acid-binding component is as defined in any one of claims 23 to 25.

43. A mixture as claimed in any one of claims 40 to 42, wherein the lipid component is as defined in any one of claims 26 to 30, 33 and 34.

44. A mixture as claimed in claim 40, which comprises an equimolar mixture of DOPE and DOTMA as the lipid component, an integrin-binding peptide as the integrin-binding component, and  $[K]_{16}$  as the polycationic component nucleic acid-binding component.

45. A mixture as claimed in claim 44, wherein the ratio lipid component:combined integrin-binding/polycationic nucleic acid-binding component is 0.75:4 by weight.

46. A process for producing a complex as claimed in claim 1, which comprises incorporating a nucleic acid with a mixture as claimed in any one of claims 40 to 45.

47. A pharmaceutical composition which comprises a complex as claimed in any one of claims 1 to 32 or claim 35, in admixture or conjunction with a pharmaceutically suitable carrier.

48. A method of transfecting cells with a nucleic acid, which comprises contacting the cells in vitro or in vivo with a complex as claimed in any one of claims 1 to 36 or claim 39 under conditions suitable for effecting transfection.

49. A method for the treatment or prophylaxis of a condition caused in human or in a non-human animal by a defect and/or a deficiency in a gene, which comprises administering a complex as claimed in any one of claims 1 to 36 or claim 39 to the human or to the non-human animal.

50. A method for therapeutic or prophylactic immunisation of a human or of a non-human animal, which comprises administering a complex as claimed in any one of claims 1 to 36 or claim 39 to the human or to the non-human animal.

51. A method of anti-sense therapy, which comprises

- 83 -

administering a complex as claimed in any one of claims 1 to 36 or claim 39 to a human or to a non-human animal.

52. A method as claimed in claim 48, wherein the cells are also contacted with an agent that disrupts cell-cell functions.

53. A method as claimed in claim 52, wherein the cells are confluent cells or are cells that are slowly dividing cells or are non-dividing cells.

54. A method as claimed in claim 53, wherein the cells are a confluent monolayer.

55. A method as claimed in claim 53, wherein the cells are a tissue, especially a tissue comprising slowly dividing cells or non-dividing cells.

56. A method as claimed in any one of claims 52, 53 and 55, wherein the cells are a tissue comprising an endothelium or an epithelium.

57. A method as claimed in any one of claims 52 to 56, wherein the agent that is capable of disrupting cell-cell junctions is a calcium-binding or calcium chelating agent.

58. A method as claimed in claim 57, wherein the calcium binding or calcium chelating agent is EGTA.

59. A method as claimed in claim 58, wherein EGTA is used at a concentration of 1mM or less, for example, from about 0.5 to 1 mM, especially about 1 mM *in vitro* or 25 to 200 nM, for example, 100 mM, *in vivo*.

60. A method as claimed in any one of claims 52 to 56, wherein the agent that is capable of disrupting cell-cell junctions is an antibody directed to a substance involved in cell adhesion.

61. A method as claimed in claim 60, wherein the antibody directed to a substance involved in cell adhesion is an anti-cadherin.

62. A method as claimed in any one of claims 52 to 61, wherein the agent that disrupts cell-cell junctions is used at the same or substantially the same time as the complex.

63. A method as claimed in any one of claims 49 to 51, wherein an agent that disrupts cell-cell functions is used in conjunction with the complex.

64. A method as claimed in claim 63, wherein the agent that disrupts cell-cell functions is as defined in any one of claims 57 to 62.

65. A complex as claimed in any one of claims 1 to 36 or claim 39 for use as a medicament or a vaccine.

66. Use of a complex as claimed in any one of claims 1 to 36 or claim 39 for the manufacture of a medicament for the prophylaxis of a condition caused in a human or a non-human animal by a defect and/or a deficiency in a gene, or for therapeutic or prophylactic immunisation, or for anti-sense therapy.

67. A complex as claimed in claim 65 or a use as claimed in claim 66, wherein an agent that disrupts cell-cell functions is used in conjunction with the complex., the agent that disrupts cell-cell functions preferably being as defined in any one of claims 57 to 62.

68. A kit that comprises (i) an integrin-binding component, (ii) a polycationic nucleic acid-binding component, and (iii) a lipid component, in which the integrin binding component comprises an integrin-binding element and a spacer element, the

- 85 -

spacer element being longer and/or more hydrophobic than the dipeptide spacers GG (glycine-glycine) and GA (glycine-alanine) and optionally an agent that disrupts cell-cell functions.

69. A peptide XSXGA [SEQ. ID NO.:18] in which X =  $\epsilon$  aminohexanoic acid, S = serine and G = glycine.

1/12

Fig.1.




Fig.3.





Fig.2.



3/12

Fig.4.





Fig.5.



4/12




Fig. 6A.




Fig. 6B.




Fig. 6C.




Fig. 6D.

5/12

Fig.7.





Fig.8.



6/12

Fig.9.





Fig.10.



7/12

Fig.11.









Fig.12.




SUBSTITUTE SHEET (RULE 26)

**Fig. 13A.****Fig. 13B.****Fig. 13C.**

9/12


Fig.14.



SUBSTITUTE SHEET (RULE 26)

10/12

Fig. 15.



11/12

Fig.16A.




Fig.16B.





Fig.16C.



SUBSTITUTE SHEET (RULE 26)

12/12

Fig.17A.




Fig.17B.




Fig.17C.




Fig.17D.




Fig.17E.




Fig.17F.




Fig.17G.





Fig.17H.



## SEQUENCE LISTING

<110> ICH Productions Limited

<120> Integrin-Targeting Vectors Having Enhanced Transfection Activity

<130> 6176 JSvn/TJH

<140>

<141>

<160> 37

<170> PatentIn Ver. 2.1

<210> 1

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide

<400> 1

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Lys Lys Lys Lys  
1 5 10 15

Lys  
20 25

<210> 2

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide

<400> 2

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Lys Lys Lys Lys Lys  
1 5 10 15

Lys  
20 25

<210> 3

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide

<400> 3

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Lys Lys Lys Lys Lys Lys Lys Lys Lys  
20 25

<210> 4

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide

<400> 4

Lys  
1 5 10 15

Gly Ala Cys Arg Gly Asp Met Phe Gly Cys Ala  
20 25

<210> 5

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide

<400> 5

Cys Arg Gly Asp Met Phe Gly Cys  
1 5

<210> 6

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide

<400> 6

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys  
1 5 10

<210> 7

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide

<400> 7  
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly  
1 5 10

<210> 8  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 8  
Gly Gly Cys Arg Gly Asp Phe Gly Cys Ala  
1 5 10

<210> 9  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 9  
Gly Ala Cys Arg Gly Asp Met Phe Gly Cys Ala  
1 5 10

<210> 10  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 10  
Gly Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Ala  
1 5 10

<210> 11  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 11  
Gly Ala Cys Arg Arg Glu Thr Ala Trp Ala Cys Ala  
1 5 10

<210> 12  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 12  
Gly Ala Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly  
1 5 10

<210> 13  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 13  
Cys Arg Arg Glu Thr Thr Ala Trp Ala Cys  
1 5 10

<210> 14  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 14  
Gly Ala Cys Arg Gly Asp Met Phe Gly Cys Gly Gly  
1 5 10

<210> 15  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 15  
Gly Ala Gly Pro Glu Ile Leu Asp Val Pro Ser Thr  
1 5 10

<210> 16  
<211> 10  
<212> PRT  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Peptide

&lt;400&gt; 16

Gly Ala Cys Gln Ile Asp Ser Pro Cys Ala  
1 5 10

&lt;210&gt; 17

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Peptide

&lt;400&gt; 17

Gly Ala Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly Lys Gly Ala Cys  
1 5 10 15Arg Arg Glu Thr Ala Trp Ala Cys Gly  
20 25

&lt;210&gt; 18

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Peptide.  
Xaa=(Epsilon)-amino hexanoic acid

&lt;400&gt; 18

Xaa Ser Xaa Gly Ala  
1 5

&lt;210&gt; 19

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Peptide

&lt;400&gt; 19

Cys Arg Gly Asp Met Phe Gly Cys Gly  
1 5

&lt;210&gt; 20

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Peptide

<400> 20  
Cys Arg Gly Asp Met Phe Gly Cys Ala  
1 5

<210> 21  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 21  
Cys Asp Cys Arg Gly Asp Cys Phe Cys Ala  
1 5 10

<210> 22  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 22  
Cys Arg Arg Glu Thr Ala Trp Ala Cys Ala  
1 5 10

<210> 23  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 23  
Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly  
1 5 10

<210> 24  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 24  
Cys Arg Gly Asp Met Phe Gly Cys Gly Gly  
1 5 10

<210> 25  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 25  
Gly Pro Glu Ile Leu Asp Val Pro Ser Thr  
1 5 10

<210> 26  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 26  
Cys Gln Ile Asp Ser Pro Cys Ala  
1 5

<210> 27  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 27  
Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly Lys Gly Ala Cys Arg Arg  
1 5 10 15  
Glu Thr Ala Trp Ala Cys Gly  
20

<210> 28  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 28  
Lys  
1 5 10 15  
Gly Ala Cys Ala Thr Arg Trp Ala Arg Glu Cys Gly

20

25

<210> 29  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide.  
Xaa=(Epsilon)-amino hexanoic acid

<400> 29  
Lys  
1 5 10 15

Xaa Ser Xaa Gly Ala Cys Arg Glu Thr Ala Trp Ala Cys Gly  
20 25 30

<210> 30  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 30  
Lys  
1 5 10 15

<210> 31  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 31  
Lys  
1 5 10 15

Gly Ala Cys Arg Gly Asp Met Phe Gly Cys Ala  
20 25

<210> 32  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

&lt;400&gt; 32

Lys Gly  
1 5 10 15

Ala Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly  
20 25

&lt;210&gt; 33

&lt;211&gt; 27

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Peptide

&lt;400&gt; 33

Lys  
1 5 10 15

Gly Ala Cys Arg Gly Asp Met Phe Gly Cys Ala  
20 25

&lt;210&gt; 34

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Peptide

&lt;400&gt; 34

Lys  
1 5 10 15

Gly Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Ala  
20 25

&lt;210&gt; 35

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Peptide

&lt;400&gt; 35

Lys  
1 5 10 15

Gly Ala Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly  
20 25

&lt;210&gt; 36

<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 36  
Lys  
1 5 10 15  
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Ala  
20 25

<210> 37  
<211> 26  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Peptide

<400> 37  
Lys  
1 5 10 15  
Gly Ala Cys Gln Ile Asp Ser Pro Cys Ala  
20 25

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number  
WO 01/092542 A3(51) International Patent Classification<sup>7</sup>: C12N 15/88, C07K 7/06, 7/08, A61K 48/00

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/GB01/02394

(22) International Filing Date: 30 May 2001 (30.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0013089.8 30 May 2000 (30.05.2000) GB  
0013090.6 30 May 2000 (30.05.2000) GB  
60/287,410 1 May 2001 (01.05.2001) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): ICH PRODUCTIONS LIMITED [GB/GB]; 30 Guildford Street, London WC1N 1EH (GB).

Published:  
— with international search report

(72) Inventor; and

(75) Inventor/Applicant (for US only): HART, Stephen, Lewis [GB/GB]; Division of Cell and Molecular Biology, Institute of Child Health, 30 Guilford Street, London WC1N 1EH (GB).

(88) Date of publication of the international search report:  
30 May 2003


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agents: SILVESTON, Judith et al.; Abel &amp; Imray, 20 Red Lion Street, London WC1R 4PQ (GB).

(54) Title: INTEGRIN-TARGETING VECTORS HAVING ENHANCED TRANSFECTION ACTIVITY



WO 01/092542 A3



(57) Abstract: A complex that comprises: i) a nucleic acid; ii) an integrin-binding component; iii) a polycationic nucleic acid-binding component, for example, oligolysine; and iv) a lipid component, for example, a cationic liposome, in which complex the integrin binding component comprises an integrin-binding element and a spacer element, the spacer element being longer and/or more hydrophobic than the dipeptide spacers GG (glycine-glycine) and GA (glycine-alanine), has enhanced transfection activity.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 01/02394A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N15/88 C07K7/06 C07K7/08 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 40502 A (LIFE TECHNOLOGIES INC) 17 September 1998 (1998-09-17)	1-4, 7-14, 18-51, 65-68
Y	table 2 ---	5
Y	WO 93 18759 A (BAYLOR COLLEGE MEDICINE) 30 September 1993 (1993-09-30) claim 11 ---	5
Y	WO 96 05218 A (CAMERON FIONA HELEN ;JENNINGS PHILIP ANTHONY (AU); BENDER VERONIKA) 22 February 1996 (1996-02-22) claims 14,30,42,53; examples 1,2 ---	5
		-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

18 March 2002

Date of mailing of the international search report

07.06.02

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Lonnoy, 0

## INTERNATIONAL SEARCH REPORT

Int	lational Application No
PCT/GB 01/02394	

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 40214 A (RIORDAN CATHERINE O ;GENZYME CORP (US); ROMANCZUK HELEN (US); WADS) 12 August 1999 (1999-08-12) claim 15; table 1 ---	13,14
A	WO 99 60110 A (UNIV TENNESSEE RES CORP) 25 November 1999 (1999-11-25) claim 39 ---	15
A	WO 98 07865 A (GENVEC INC) 26 February 1998 (1998-02-26) SeqIdNo.35 ---	16,17
A	WO 98 54347 A (HART STEPHEN LEWIS ;INST OF CHILD HEALTH (GB)) 3 December 1998 (1998-12-03) cited in the application ---	
A	HART S L: "INTEGRIN-MEDIATED VECTORS FOR GENE TRANSFER AND THERAPY" CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON, GB, vol. 1, no. 2, April 1999 (1999-04), pages 197-203, XP001055320 ISSN: 1464-8431 ---	
A	WO 99 58694 A (UNIV CALIFORNIA) 18 November 1999 (1999-11-18) claim 59 ---	
A	WO 95 14714 A (JOLLA CANCER RES FOUND) 1 June 1995 (1995-06-01) cited in the application -----	

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 01/02394

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 48-51, as far as they relate to *in vivo* methods, are directed to methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-51, 65, 66, 69, all totally and 67, 68 both partially

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-51, 65, 66, 69 (all totally) and 67, 68 (both partially)

A complex comprising a nucleic acid, an integrin-binding component, a polycationic nucleic acid-binding component, and a lipid component, wherein the integrin-binding component comprises an integrin-binding element and a spacer element, the spacer element being longer and/or more hydrophobic than the dipeptide spacers GG and GA; applications thereof

2. Claims: 57-59 (all totally) and 52-56, 62-64, 67, 68 (all partially)

A method of transfecting cells with a nucleic acid comprising the step of contacting the cells with an agent that disrupts cell-cell functions; said method wherein said agent is a calcium-binding or calcium chelating agent.

3. Claims: 60, 61 (both totally) and 52-56, 62-64, 67, 68 (all partially)

A method of transfecting cells with a nucleic acid comprising the step of contacting the cells with an agent that disrupts cell-cell functions; said method wherein said agent is an antibody directed to a substance involved in cell-adhesion.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No  
PCT/GB 01/02394

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9840502	A 17-09-1998	US 6051429 A AU 6562298 A EP 1007699 A1 JP 2001517939 T US 6376248 B1 WO 9840502 A1		18-04-2000 29-09-1998 14-06-2000 09-10-2001 23-04-2002 17-09-1998
WO 9318759	A 30-09-1993	AU 671450 B2 AU 3966893 A CA 2131620 A1 EP 0632722 A1 JP 7505283 T WO 9318759 A1 US 6033884 A US 5994109 A US 6150168 A US 6177554-B1		29-08-1996 21-10-1993 30-09-1993 11-01-1995 15-06-1995 30-09-1993 07-03-2000 30-11-1999 21-11-2000 23-01-2001
WO 9605218	A 22-02-1996	AU 684383 B2 AU 3158595 A WO 9605218 A1 CA 2197653 A1 CN 1158619 A EP 0777679 A1 FI 970648 A JP 10509862 T NZ 290757 A RU 2160278 C2 US 5906922 A NO 970651 A		11-12-1997 07-03-1996 22-02-1996 22-02-1996 03-09-1997 11-06-1997 07-04-1997 29-09-1998 29-09-2000 10-12-2000 25-05-1999 02-04-1997
WO 9940214	A 12-08-1999	AU 2662999 A CA 2318981 A1 EP 1053342 A2 WO 9940214 A2 US 6287857 B1		23-08-1999 12-08-1999 22-11-2000 12-08-1999 11-09-2001
WO 9960110	A 25-11-1999	AU 4089899 A WO 9960110 A2		06-12-1999 25-11-1999
WO 9807865	A 26-02-1998	US 5846782 A AU 724189 B2 AU 1086897 A AU 732770 B2 AU 4080497 A BG 102554 A BR 9612685 A CZ 9801623 A3 EE 9800160 A EP 0863987 A2 EP 0920514 A1 HU 0001120 A2 JP 2001503250 T JP 11501219 T NO 982417 A NZ 323834 A PL 327038 A1 SK 72298 A3		08-12-1998 14-09-2000 19-06-1997 26-04-2001 06-03-1998 30-04-1999 20-07-1999 14-10-1998 15-12-1998 16-09-1998 09-06-1999 28-07-2000 13-03-2001 02-02-1999 06-07-1998 28-01-2000 09-11-1998 02-12-1998

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/GB 01/02394

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9807865	A	WO 9720051 A2		05-06-1997
		WO 9807865 A1		26-02-1998
		US 6057155 A		02-05-2000
		US 6329190 B1		11-12-2001
WO 9854347	A 03-12-1998	AU 7667398 A		30-12-1998
		EP 1003898 A1		31-05-2000
		WO 9854347 A1		03-12-1998
		JP 2002502243 T		22-01-2002
		US 2002042384 A1		11-04-2002
WO 9958694	A 18-11-1999	US 6210707 B1		03-04-2001
		AU 3983499 A		29-11-1999
		CA 2330741 A1		18-11-1999
		EP 1078079 A1		28-02-2001
		WO 9958694 A1		18-11-1999
		US 2002001612 A1		03-01-2002
WO 9514714	A 01-06-1995	US 5981478 A		09-11-1999
		AU 682561 B2		09-10-1997
		AU 1259695 A		13-06-1995
		DE 69427370 D1		05-07-2001
		DE 69427370 T2		18-04-2002
		EP 0730607 A1		11-09-1996
		EP 0906919 A2		07-04-1999
		JP 9509142 T		16-09-1997
		WO 9514714 A1		01-06-1995
		US 5627263 A		06-05-1997



## CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number  
WO 01/092542 A3(51) International Patent Classification<sup>7</sup>: C12N 15/88,  
C07K 7/06, 7/08, A61K 48/00CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW.

(21) International Application Number: PCT/GB01/02394

(22) International Filing Date: 30 May 2001 (30.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0013089.8 30 May 2000 (30.05.2000) GB  
0013090.6 30 May 2000 (30.05.2000) GB  
60/287,410 1 May 2001 (01.05.2001) US(71) Applicant (for all designated States except US): ICH  
PRODUCTIONS LIMITED [GB/GB]; 30 Guildford  
Street, London WC1N 1EH (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): HART, Stephen,  
Lewis [GB/GB]; Division of Cell and Molecular Biology,  
Institute of Child Health, 30 Guilford Street, London  
WC1N 1EH (GB).(74) Agents: SILVESTON, Judith et al.; Abel & Imray, 20  
Red Lion Street, London WC1R 4PQ (GB).(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
30 May 2003(48) Date of publication of this corrected version:  
24 December 2003(15) Information about Correction:  
see PCT Gazette No. 52/2003 of 24 December 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/092542 A3

(54) Title: INTEGRIN-TARGETING VECTORS HAVING ENHANCED TRANSFECTION ACTIVITY

(57) Abstract: A complex that comprises: i) a nucleic acid; ii) an integrin-binding component; iii) a polycationic nucleic acid-binding component, for example, oligolysine; and iv) a lipid component, for example, a cationic liposome, in which complex the integrin binding component comprises an integrin-binding element and a spacer element, the spacer element being longer and/or more hydrophobic than the dipeptide spacers GG (glycine-glycine) and GA (glycine-alanine), has enhanced transfection activity.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

**BLACK BORDERS**

**IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

**FADED TEXT OR DRAWING**

**BLURRED OR ILLEGIBLE TEXT OR DRAWING**

**SKEWED/SLANTED IMAGES**

**COLOR OR BLACK AND WHITE PHOTOGRAPHS**

**GRAY SCALE DOCUMENTS**

**LINES OR MARKS ON ORIGINAL DOCUMENT**

**REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

**OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**